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ABSTRACT 
By developing a high-density murine immunophenotyping platform compatible with high-
throughput genetic screening, we have established profound contributions of genetics and 
structure to immune variation (www.immunophenotype.org). Specifically, high-
throughput phenotyping of 530 unique mouse gene knockouts identified 140 monogenic 
“hits”, of which most had no previous immunological association. Furthermore, hits were 
collectively enriched in genes for which humans show poor tolerance to loss-of-function. 
The immunophenotyping platform also exposed dense correlation networks linking 
immune parameters with one another and with specific physiologic traits. Such linkages 
limit freedom-of-movement for individual immune parameters, thereby imposing 
genetically regulated “immunological structures”, whose integrity was associated with 
immunocompetence. Hence, we provide an expanded genetic resource and structural 
perspective for understanding and monitoring immune variation in health and disease. 
 
  
The increasing implication of immunology in myriad arenas of pathophysiology emphasises 
the importance of understanding and appropriately measuring inter-individual immune 
variation. Reflecting this are highly informative studies describing human immune system 
dynamics1-4, and investigations of the factors contributing to it5-8. Thus, SNP-based and deep 
sequencing-based Genome-Wide Association Studies (GWAS) and Twin-studies have 
associated defined genetic loci with autoimmunity and/or immunodeficiency9-14. However, it 
can be challenging to link discrete immunophenotypes to specific genes and/or genetic 
variants15. Conversely, Mendelian trait analysis, that is expanding through genome 
sequencing of “rare diseases”16,17, has established concrete links between specific genes and 
immune function. Nonetheless, this approach can be limited by the infrequency and 
uncertain clinical annotation of patients, and by practical limitations on phenotypic assays. 
 
At the same time, sex, age, and environmental factors, including diet and the microbiome, 
make major contributions to human immune variation5,6,8, but assessing their full impacts is 
limited by appropriate constraints on interventions, and by human genetic diversity. In sum, 
immunoregulatory factors seem so numerous and diverse that resolving their individual 
contributions can seem intractable. 
 
In this regard, animal model studies offer unique opportunities. Specifically, use of an inbred 
strain limits genetic variation; co-housing reduces microbiome and dietary variation; and age-
matching limits physiologic variation. Thus, their study can establish a frame-of-reference for 
the nature and sources of variation in the “baseline immune system”. That frame-of-
reference can aid myriad investigations of rodent immunology, and guide the design and 
interpretation of human immunological studies. Indeed, despite their limitations, gene 
knockout mouse studies have usefully modelled several human immunopathologies and the 
actions of many of the most widely prescribed medicines18.  Superimposed upon this, the use 
of co-housed, age-matched mice for a genetic screen could offer insight into the fraction and 
nature of genes whose loss-of-function perturbs the immune system.  
 
To achieve these goals at scale, we have developed a robust, broadly transferrable, high-
density, high-throughput Infection and Immunity Immunophenotyping (“3i”) platform that 
has facilitated analysis of the baseline immune system and its response to challenge in aged-
matched, co-housed, isogenic mouse strains collectively mutated in 530 genes 
(www.immunophenotype.org). Additionally, by integrating 3i into the International Mouse 
Phenotyping Consortium (IMPC) pipeline (www.mousephenotype.org), immune variation 
could be related to measures of general physiology. The expansive outputs (>1million data-
points) have provided many discrete insights and data-rich resources that collectively build a 
revised frame-of-reference for viewing immune variation. Moreover, of 530 genes screened, 
the baseline immunophenotype and/or responses to challenge were affected by mutations 
in 140 genes (>25% hit-rate), most of which (57%) were never hitherto associated with 
immunobiology, but which were strikingly enriched in genes for which humans show little 
tolerance to loss-of-function.  
 
Results 
Immunophenotyping of mutant mice at scale 
The IMPC aims to obtain and publicly disseminate phenotyping data for mice with targeted 
disruptions in each of ~18,000 annotated protein-coding genes, generated using either 
embryonic stem cells generated by the International Knockout Mouse Consortium19 or 
CRISPR technology. Although full-gene knockouts do not model most forms of human genetic 
variation, they can irrefutably implicate defined molecular processes in immunophenotypes, 
and those phenotypes may be directly related to biallelic human loss-of-function variants, 
revealed by studies of communities with parental relatedness20. 
 
Contributing to IMPC, the Wellcome Trust Sanger Institute (WTSI) generated ~3 mutant lines 
per week. Given this scale, immunological assays were limited to peripheral blood 
lymphocytometry and responses to Salmonella and Citrobacter infection21 (Fig 1a; 
Supplementary Fig. 1a), potentially missing many immunoregulatory genes. We therefore 
developed a high-density infection and immunity immunophenotyping platform (3i) 
compatible with the IMPC high-throughput screen (HTS), that permitted us to assess the 
proportion and types of genes that may underpin immune variation. Moreover, by integration 
into IMPC, 3i could relate immunophenotypes to general physiological traits.  
 
At homeostasis, the baseline immune system is simultaneously poised to respond to 
infectious or toxic challenges and regulated to limit immunopathology. Hence, inter-
individual baseline variation is likely manifest in differential immunocompetence and 
susceptibilities to autoimmune diseases. To capture this, 3i featured high-content flow 
cytometry analysis of lymphoid and myeloid cells and their activation states in spleen (SPL), 
mesenteric lymph nodes (MLN), bone marrow (BM) and peripheral blood (PB) at steady-state 
(Fig 1a; panels in Supplementary Table 1; populations quantitated in Supplementary Table 2; 
illustrative gating strategy for MLN T, NKT, and NK cell subsets shown in Supplementary Fig 
1b; for other gating, see materials and methods). To sample an extra-lymphoid immune 
system, quantitative object-based imaging was applied to intraepidermal lymphoid and 
myeloid cells in situ (Supplementary Fig 1c). Anti-nuclear antibodies (ANA) were quantitated, 
since they commonly reflect impaired immunological tolerance (Supplementary Fig 1d), while 
effector potential was gauged by measuring SPL CD8 T cell-mediated cytolysis.  
 
All observational assays requiring sacrifice were conducted at the IMPC termination-point of 
16 weeks so that they neither diverted tissue from, nor operationally interfered with the basic 
phenotyping programme. Measuring absolute numbers of cells was largely precluded by 
IMPC requirements on organ usage, although the focus on percentage representation reflects 
common practice in immune monitoring2,3,5. In parallel, mice were assayed for responses to 
infection by a parasite (Trichuris muris), a virus (influenza), and a bacterium (Salmonella 
typhimurium), and to sodium dextran sulphate (DSS) that causes gut epithelial erosion and 
microbial translocation (Fig 1a; Supplementary Fig 1e). For each 3i component, experimental 
standard-operating procedures were established and stringently quality-controlled; 
instruments were well calibrated; and data reproducibility monitored longitudinally, with 
automated analysis minimizing any temporal variation (Supplementary Fig 1f). Additionally, 
and to comply with time and budgetary constraints typical of an HTS, we chose minimum 
numbers of data-points required to establish significance following application of bespoke 
statistical analyses (Fig 1a; Supplementary Table 3).  
 
This study represents a five-year phase in which 3i phenotyped knockout strains for 530 genes 
(Supplementary Table 4). Most strains were nulls or severe hypomorphs of protein-coding 
genes, whereas 1.8% were lncRNA or miRNA mutants. For ~30% of genes, heterozygotes were 
screened because homozygotes were embryonically lethal or sub-viable. Of genes selected, 
9% had been identified in GWAS screens for inflammatory bowel disease (IBD) or were linked 
to infection; some others had GWAS associations to non-immunological traits; and the 
majority were poorly understood genes, thereby maximising the potential for discovery. 
Panther Biological Process Gene Ontology showed that relative to the whole genome, the 
selected genes were neither enriched nor depleted in categories with immunological 
annotations, a point illustrated by a GO-Slim analysis in which the only categories with low 
but significant deviation from the whole genome were reproduction and protein modification 
(Supplementary Fig 1g – indicated by asterisks).  
 
Overall, >1 million data-points were collected from 7 distinct steady-state assay systems 
applied to 2,100 -10,000 mice (Fig 1a), while additional cohorts of mice were subjected to 
challenges. Moreover, minimization of technical variation; fastidious control over batch 
variation, e.g. by spreading phenotyping of each strain over several separate experiments; 
optimization of data collection and analysis22; and innovative data management across 
heterologous platforms permitted 3i to make rigorous assessments of naturally-arising 
variation in the baseline immune system of many hundreds of genetically identical, age-
matched, co-located, adult C57BL/6N mice, thereby creating a precise backdrop for analyzing 
mutants. 
 
Immunophenotypic variation among controls 
Most steady-state immune cell subsets in adult C57BL/6N controls showed low coefficients 
of variation (CV), which were further reduced by dynamic automated gating of flow cytometry 
data, particularly for numerically small cell subsets whose reproducible quantitation can be 
challenging (Supplementary Fig 1h). Hence, automated gating was adopted screen-wide to 
obtain the population sizes and CVs described in Fig 1b (see also Materials and Methods)22. 
The screen revealed greater variation for some cell types, including germinal centre (GC) B 
cells and various αβ and γδ T cell subsets expressing an activation marker, KLRG1 (Fig 1b; 
bottom-most panel). Activation-driven variation of adaptive subsets was anticipated since 
non-heritable, antigen receptor gene rearrangements dictate that syngeneic individuals 
respond differently to shared environments. Nonetheless, effects were highly selective, as 
evidenced by low CVs of KLRG1+ CD4 T helper cells and of KLRG1+ regulatory T cells (Treg cells) 
compared to a comparably-sized subset of KLRG1+ CD8 T cells (Fig 1b, compare top and 
bottom-most panels for subsets denoted with blue arrows). 
 Compared to most innate immune cell subsets, SPL and PB neutrophils showed relatively high 
CVs, particularly in males. Indeed, sex was a consistent source of variation for ~50% of PB, 
SPL, BM, and MLN cell subsets, reflected either in significantly different variance for female 
(F) and male (M) mice, e.g. for PB neutrophils (Fig 1c; left panel) and displayed broadly in Fig 
1b (bottom panel - CVF, blue circles; CVM, orange circles), and/or in sexually dimorphic mean-
values, e.g. for BM B cell progenitors (Fig 1c; right panel), and displayed broadly in Fig 1b 
(middle panel; meanF/meanM log2-transformed). Considered at scale, the impact of sex was 
such that principal component analysis (PCA) of 60 aggregated SPL, MLN, BM, and PBL flow 
cytometry parameters sex-segregated 451 mice with >99% accuracy, with the first two 
principal components explaining 34% of total variation (Fig 1d).  
 
Several properties of Vγ5+ dendritic epidermal T cells (DETC) and Langerhans Cells (LC) were 
also sexually dimorphic, as were ANA outputs, evoking frequent gender imbalances in human 
autoimmunity (Supplementary Fig 1i)23. Conversely, DSS outputs did not segregate by sex, 
evoking gender-neutral incidences of IBD (Supplementary Fig 1i)24. In sum, widespread but 
highly selective sexual dimorphism characterizes the baseline immune system of adult 
C57BL/6N mice. As a practical response to this, all statistical tests of 3i data accounted for 
sex. 
 
Significant correlations of discrete immune parameters 
Although the immune system is multi-component, the inter-connectedness of its constituent 
cell populations is poorly understood. In this regard, the 3i analysis of >650 age-matched, co-
located, genetically identical control mice identified significant positive (red) and negative 
(blue) correlations, as illustrated for 46 steady-state SPL parameters in male and female mice 
(Fig 2a; Supplementary Fig 2): note, all correlations shown exclude contingent relationships 
reflecting nested or directly paired technical measurements (see Supplementary Fig 1b; 
Materials and Methods). Conversely, the strong, negative, steady-state relationship of 
effector CD44+CD62L-CD8+ T cells to naive CD44-CD62L+CD8+ T cells is not contingent, since 
there is a variable population of resting CD44+CD62L+CD8+ T cells. 
 
As illustrated by male and female SPL data-sets (Fig 2a, Supplementary Fig 2), correlations 
included a “lymphoid activation-cluster” embracing effector CD4+, CD8+, NK and  T cells; Treg 
cells; conventional DC; and plasma cells (Fig 2a, Supplementary Fig 2; central red core). While 
some such correlations were anticipated, e.g. effector Th with effector Treg cells, others were 
not, e.g. effector CD8+ T cells correlated positively with plasma cells (Fig 2a, 27 down, 23 
across) but negatively with effector NK cells (Fig 2a, 27 down, 9 across). Such relationships 
may inform the design and monitoring of vaccines aimed at eliciting discrete effector 
responses. 
 
Other correlations were related to immune homeostasis: thus, higher NK cell representation 
reflected increases in mature NK cells (Fig 2a, 5 down, 9 across), whereas higher CD8+ T cell 
representation reflected increases in resting but not effector CD8+ T cells (Fig 2a, 45 down 
versus 46 across or 27 across). Finally, some correlations seemed wholly unexplained; e.g. 
monocytes positively correlated with B1 B cells, and memory B cells positively correlated with 
T cells (Fig 2a, 34 down, 20 across; 18 down, 16 across).  
 
Many correlations were comparable in male and female mice (Fig 2a; Supplementary Fig 2; 
Fig 2b, colorless circles along the 45o axis), but some were sexually dimorphic, with R values 
and/or regression slopes being stronger in females (e.g. macrophages versus resting NK) or 
males (e.g. monocytes versus neutrophils) (Fig 2b, purple and orange circles, respectively). 
Whereas the spleen matrices shown are intra-organ, there were also many inter-organ 
correlations, collectively revealing that the baseline immune system of adult C57BL/6N mice 
is underpinned by dense, sexually dimorphic networks of >1000 correlations. These may 
reflect robust intercellular circuitry, such as exists for macrophages and fibroblasts25. 
 
Integrating immunology with physiology  
By coupling 3i to the IMPC, all animals in the observational screen were subject to measures 
of general physiology (see Fig 1a; Supplementary Fig 1a). As is well established, many 
physiologic traits are correlated with one another. By limiting the freedom-of-movement of 
individual parameters, those correlations impose phenotypic structures for female and male 
mice, reflecting sex-specific physiologies (Supplementary Fig 3a,b). Of note, the correlation 
network appeared much less dense in females, possibly because its full elucidation was 
masked by additional variation arising from sex-specific components, notably oestrous that 
cycles every 4-5 days26. This notwithstanding, core relationships were clearly conserved in 
females and males, e.g. positive correlations spanning cholesterol (Chol), HDL-cholesterol 
(HDL), insulin (Ins), and body-weight (Wght), and the relationship of total protein (Tp) to 
fructosamine (Fruct) which reflects blood protein glycation. Likewise, glucose (Gluc) 
correlated negatively with chloride (Cl) and sodium (Na). From a practical standpoint, the 
relatively low inter-individual variability of Na emphasised that prominent correlations did 
not merely reflect high dynamic ranges of specific parameters. 
 
The more consistent variation of non-immunological parameters in males versus females 
allowed us to identify many highly significant correlations between those parameters and 
specific immunological parameters, with Chol, HDL, and Na being prominent (Fig 3). Although 
immunoregulatory roles for metabolic products and processes are well documented27,28, 
identified correlations were conspicuously selective, with, for example, no overt 
immunophenotypic correlations with triglycerides, creatinine, or calcium, but many with red 
blood cell distribution width (RDW), a common marker of anaemia29, frequently associated 
with chronic immune activation30, and recently shown to predict all-cause mortality in 
humans31. 
 
Clearly, significant correlations of immune parameters one with another and with discrete 
non-immunological traits will limit the freedom-to-vary of any single immune parameter, 
thereby imposing an immunological structure, as shown for males (Fig 3a). Immunological 
structure may reflect a balance of immune and non-immunological components that delivers 
immunocompetence while limiting immunopathology. For females, the sparse correlation 
network of non-immunological parameters (Supplementary Fig 3b) dictated that the 
immunological structure was also more sparse, although HDL, RDW and Na were again 
prominent within it (Fig 3b).  
 
Many diverse genes affect the immunophenotype 
The establishment of robust ranges for myriad immune parameters across age-matched, co-
located, wild-type mice, coupled with the application of bespoke statistical tests (see Fig 1a; 
Supplementary Fig 1f; Supplementary Table 3; Materials and Methods) facilitated high-
throughput screening of knockout lines collectively mutated in 530 genes. For steady-state 
immune parameters, “phenodeviants” (“hits”) which exerted monogenic dysregulation of the 
immunophenotype were called when ≥60% of samples from a strain located outside the 95th 
percentiles of the wild-type distribution for that parameter.  
 
To further limit batch effects, each mutant strain was assayed on at least two separate 
occasions, with hits called in a supervised manner; i.e. no data-points were discarded from 
the dataset, but those possibly attributable to batch effects would not be scored as 
hits. Effects of temporal data drift in flow-cytometric data were avoided by comparing each 
knockout mouse to the 70 wild-type mice examined closest in time for any given parameter 
(Supplementary Table 3). Additionally, there was expert review of raw data for all hits and 
borderline candidates identified by the statistical pipeline.  
 
False positive rates (FPRs) for each parameter were estimated by randomly sampling sets of 
wild-type controls in accordance with the real work flow so as to mimic 10,000 different 
mutant strains, and then assessing their phenodeviance (Supplementary Fig 4a-d). Resulting 
FPRs were far below observed hit-rates that collectively identified 140 phenodeviants, an 
overall hit-rate of >25% for genes that a priori showed no collective enrichment of 
immunological GO-annotation (Fig 4; Supplementary Fig 4; see Supplementary Fig 1g). 
Approximately ~20% of hits were heterozygotes, that collectively accounted for ~30% of the 
strains analyzed. The relevant code is available at: 
https://github.com/AnnaLorenc/3i_heatmapping; note that precise hit counts for genes 
with borderline read-outs may be subject to minor adjustment, based on ongoing analyses 
and expert review.  
 
Unsurprisingly, hit-rates varied among the assays (Supplementary Fig 5a), and the importance 
of assaying the same cell populations in different organs was emphasized by the fact that 
~50% of flow cytometry hits showed no peripheral blood phenotype (hence would not have 
scored in IMPC), and of those 36% were unique to spleen, and 39% unique to MLN 
(Supplementary Fig 5b). Likewise, two thirds of challenge phenodeviants were unique to one 
pathogen (Supplementary Fig 5b). 
 Because most phenodeviants scored in only one or few assays, and because overall 3i hit-
calling was conservative (Supplementary Table 3), a 25% hit-rate for monogenic effects may 
have under-estimated the contribution of genetics to immune variation. In short, 3i might 
have identified more hits if more immunological assays had been performed. For example, no 
direct assessments of immunological memory were made, and the steady-state gut was not 
analysed because of interference with IMPC phenotyping. Additionally, although sexually 
dimorphic trends were apparent for some hits, e.g. TCR+ CD8 T cell percentages in Arpc1b–
/– mice; TCR+ Treg cell percentages in Setd5–/– mice; and low TCR+CD44+CD62L– effector 
CD4 cell percentages in male IL-27p28 deficient mice (see www.immunophenotype.org), 
some sexually dimorphic phenodeviants might not have scored because, other than for PB 
cytometry and ANA, too few mutant mice were examined. Furthermore, no thorough analysis 
was made of the genetic impact of non-coding regions.  
 
These considerations notwithstanding, it was conspicuous that the overall hit-rate was largely 
comparable irrespective of how well-studied genes were, as assessed by PubMed. 
Specifically, the hit-rate for genes in the lowest quartile of citations (from 0-26) was 23.3%, 
with the rates for the 3rd, 2nd, and 1st quartiles being 22.5%, 25% and 34%, respectively. This 
observation, combined with the fact that the genes screened collectively lacked a priori 
enrichment in any immunological annotations, permitted 3i to identify monogenic impacts 
on the C57BL/6N immune system of 80 genes never hitherto implicated in immunoregulation. 
Four case-studies, briefly considered below, illustrate the diversity of impacts of different 
phenodeviants (Figs 5, 6), while all phenodeviants are described at 
www.immunophenotype.org. 
 
Different classes of genetically regulated immune variation 
Nacc2 (Nucleus accumbens-associated protein 2) is a little-studied gene32 which specifically 
affected V5+ DETC numbers (Fig 5a,b), a phenotype hitherto limited to mice mutant for V5 
or for Skint genes that encode poorly understood, epithelial DETC-selecting elements33,34. 
Thus, the 3i screen identified a novel immune regulator with potential to inform how a 
prototypic tissue-resident T cell compartment is selected and/or maintained in adulthood. In 
this regard, occasional mice scored as harboring wild-type DETC numbers, but those cells had 
low TCR expression, consistent with incomplete selection33. 
 
Dph6–/– mice displayed an immune-specific but broad phenotype, with several innate and 
adaptive cell lineages differing significantly from wild-type (Fig 5a,c). Dph6 is ubiquitously 
expressed, encoding one of seven enzymes required for synthesizing diphthamide, a modified 
histidine residue incorporated into eukaryotic elongation factor 235. However, whereas Dph1, 
Dph3 or Dph4 deficiencies are embryonically lethal36,37, the 3i phenotype suggested an 
immune cell-specific, Dph6-dependent protein translation system of differential importance 
in different leukocyte subsets. This evokes growing evidence for immunoregulation by cell 
type-specific translation38. 
  
In the third case, the broad phenotypic perturbation of several physiologic traits in Duoxa2–/– 
mice (Fig 6a) was unsurprising, since Duoxa2 contributes critically to iodine utilisation in 
thyroid hormone synthesis39. By contrast, the significant expansions of specific immune cell 
subsets, particularly CD4+ T cells, neutrophils and eosinophils, and the decreased 
representation of blood Ly6C– monocytes and KLRG1+ NK cells in Duoxa2–/– mice (Fig 6b) were 
unanticipated given little prior implication of the gene in immunobiology. Thus, 3i identified 
a potential immunoregulatory role of Duoxa2-dependent endocrine biology. 
 
Finally, Bach2–/– mice illustrated how 3i could offer broader insights into a well-established, 
disease-related gene. BACH2 deficiencies have been associated with autoimmunity, 
inflammation, and allergy, commonly attributed to increased effector CD4+ and CD8+ T cells, 
as reported in Bach2–/– mice40-44. However, 3i also identified a greatly expanded range of 
innate and adaptive immune phenotypes of Bach2–/– mice (orange bars in Fig 6c), of which 
the most significant was a >10-fold increase in KLRG1+CD4– NK cells. Thus, some components 
of Bach2-dependent disease may reflect precocious innate immune cell activation. Moreover, 
Bach2–/– CD8+ T cells showed abnormally high cytolytic activity, and most Bach2–/– mice were 
high susceptibility to DSS-colitis (Fig 6d,e). 
 
Genetic regulators of challenge responses 
Of 86 phenodeviants affecting steady-state PB, SPL, MLN, BM, CTL, ANA or epidermal 
phenotypes, ~25% also affected responses to challenges, as judged against wild-type controls 
assayed contemporaneously (Fig 7a; Supplementary Fig 5b). Once more, those hits included 
several sparsely-studied genes (Fig 7a, green circles in upper-right quadrant). The fraction of 
phenodeviants affecting steady-state responses that also affected challenge responses might 
have been higher if 3i had employed additional challenges and/or assays of response. 
However, given the breadth of challenges utilized, and the biologically significant post-
challenge outcome metrics, including survival and weight-loss, our findings most probably 
point to greater genetic redundancy in immune function than in baseline 
immunophenotypes. Indeed, genes affecting challenge outcomes were enriched in those 
perturbing more than one steady-state parameter (Fig 7a; larger circles are relatively enriched 
in upper-right vs lower-right quadrant). High functional redundancy might ensure that 
immunocompetence would be resilient to wide-ranging inter-individual variation in baseline 
immune cell subsets, as characterises humans1-3. Finally, some phenodeviants, including 
many sparsely-studied genes, affected functional responses but not steady-state immune 
parameters (Fig 7a, upper-left quadrant; Supplementary Fig 5b), possibly because they affect 
baseline immune parameter(s) not assayed by 3i and/or are expressed by non-immune cells 
which regulate challenge responses via non-immunological mechanisms such as barrier 
protection.  
 
Given that 57% of the 3i “hits” (80/140) had never hitherto been implicated in 
immunobiology, and that the others included many little-studied genes, it was striking that 
hits were collectively enriched in genes for which humans show poor tolerance to “loss-of-
function” (LoF). For all human genes assessed by the Genome Aggregation Database 
(gnomAD) (n=16307), tolerance to LoF is illustrated by “LOEUF”: loss-of-function 
observed/expected upper bound fraction, for which 0 indicates no tolerance of loss-of-
function and 2 indicates high tolerance to loss of function (Fig 7b; left panel, red line)45,46.  
We then compared this distribution with that for human orthologues of 3i hits, but first 
excluded genes with prior GWAS or OMIM classifications that might bias toward low LOEUF 
values. This notwithstanding, the residual 3i hits (n=77) (Fig 7b; left panel, purple line) showed 
a significantly different distribution, with conspicuous enrichment for genes with lower 
LOEUF. This outcome was even more striking when contrasted with human orthologues of 3i 
genes without immune phenotypes (n=334) which collectively showed no enrichment for LoF 
intolerance (Fig 7b; left panel, blue line). 
 
It might be argued that immune hits were biased toward low LOEUF values by genes scored 
as heterozygotes because the strains were sub-viable. Indeed, LOEUF values were 
conspicuously low when only heterozygotes were scored for human orthologues of all 3i hits, 
or for 3i hits minus the OMIM/GWAS genes (as above) (Fig 7b, middle panel, green and purple 
lines, respectively). Nonetheless, those low-LOEUF-value distributions were significantly 
displaced from that of human orthologues of 3i heterozygotes that were not immune hits (Fig 
7b; middle panel, blue line), strongly arguing that the low LOEUF scores for hits assessed as 
heterozygotes were not attributable solely to sub-viability but probably also to their immune 
phenodeviance. 
 
Interestingly, enrichment for low LOEUF was also apparent for human orthologues of genes 
purely with steady-state flow cytometry phenotypes (p=0.014, Wilcoxon) (Fig 7b; right hand 
panel, orange versus blue lines). Seemingly consistent with this, the 140 immunological 
phenodeviants were strikingly enriched in genes that also had non-immunological 
phenotypes (58/140 [>41%]) relative to the genes that were not hits (91/390 [23%]), with 
almost identical enrichment seen for genes affecting only baseline immune variation (39/86 
[>45%]) versus those that did not (110/444 [25%]) (Fig 7c). 
 
Genetic regulation of correlation networks 
The 3i data-sets were next used to ask whether genes affecting one or more steady-state 
immune parameter(s) might segregate according to whether they also disrupted correlations 
connecting immune parameters: i.e. whether they perturbed immunological structure. Fig 8a 
(left panel) schematises hypothetical distribution clouds of data-points for three 
phenodeviants (yellow, pink, green) displaying extreme values for cell population B. Of note, 
whereas gene yellow and gene green maintained proportionality with population A, gene pink 
broke that correlation.  
 
Real examples of this are shown in Fig 8b: Gmds and Arpc1b mutants displayed very few NK 
cells but maintained proportionality with mature NK cells, whereas most Arhgef1–/– and 
Pclaf1–/– mice sat outside the confidence limits of the relationship, displaying 
disproportionately high NK maturation. Likewise, Duxoa2–/– and Dph6–/– mice, whose effector 
CD4+ T cell numbers were atypically low and high, respectively, each preserved an inverse 
relationship of effector CD4+ Th cells and naïve CD8+ T cells, whereas this correlation was 
broken by Gmds and Cog6 deficiencies. Hence, correlations that confer structure on the 
immune system are differentially resilient to genetic perturbation. 
 
Overall, we observed that genes with the potential to affect >10 correlates collectively 
preserved ~75% of intra-organ and inter-organ correlations (Fig 8c; left-hand column, ‘Total’). 
Thus, immunological structure was relatively resilient to genetic perturbation of discrete 
immune parameters. Nonetheless, mutations of some genes that affected larger numbers of 
immune parameters disrupted substantially more correlations, as was evident for Cog6 and 
Bach2 (Fig 8c). However, structural perturbation did not simply reflect the greater number of 
immunophenotypes affected by a gene, since Dph6–/– mice displayed a similar number of 
steady-state immunophenotypes (e.g. altered cell subsets) to Cog6–/– mice, but preserved 
most intra-organ and inter-organ correlations (Fig 8d; compare the density of red lines 
(broken correlations) versus blue lines (preserved correlations) in the spleens of the two 
strains). This argues that specific genes underpin the existence of certain correlations and 
hence shape immunological structure. Added to this, Arpc1b broke many inter-organ 
correlations while preserving most intra-organ correlations (Fig 8c), indicating that different 
genes regulate immune subset relationships in different ways. 
 
Given that many immune parameters also correlated with specific physiologic measures, it 
was appropriate to ask whether genes with non-immunological phenotypes were more likely 
to disrupt immunological structure. Indeed, baseline immunological structure seemed much 
less resilient when discrete physiological traits were perturbed, with such genes collectively 
breaking significantly more correlations (30%) than did genes only affecting immune 
parameters (16%) (Fig 8e). Additionally, genes which affected challenge responses as well as 
the baseline immunophenotype broke significantly more correlations (35%) than genes 
affecting only the baseline immunophenotype (19%) (Fig 8f).   By using cluster-robust 
standard errors, the results shown in Fig. 8e and 8f were robust vis-a-vis different genes 
contributing to different numbers of correlations, and correlations being underpinned by 
additional factors not tested for. Moreover, controlling for the influence of non-immune traits 
and challenge responses in the same regression analysis confirmed that non-immune and 
challenge phenotypes made separate contributions. Clearly, the association of defects in 
immunocompetence with compromises in baseline immunological structure makes a 
compelling case for assessing and better understanding immune subset correlations as a 
refined means for monitoring immune variation.  
 
Discussion 
3i has provided a community resource in the form of a broadly transferrable, high-throughput 
platform by which immunophenotypes can be measured in different settings; e.g. comparison 
of genotypic variants, or pre- and post-treatments. By combining genetic screening and 
immunophenotyping at scale, 3i has affirmed a substantial contribution of genetics to 
immunophenotypic variation, and has considerably expanded the number and diversity of 
genes known to have monogenic impacts on steady-state immune parameters and/or 
challenge responses. Those genes, most of which lacked prior implication in immunobiology, 
likely have disease-relevance given their wholly unanticipated enrichment in genes for which 
humans show poor tolerance to loss-of-function. Moreover, for well-studied genes such as 
Bach2, 3i identified hitherto unrealised endophenotypes that may contribute to disease 
mechanisms. 
 
Of comparable value to 3i’s identification of immunoregulatory genes was the functional 
implication of pathways on which those genes lie. Complex, multigenic autoimmune 
pathologies such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS) reflect 
combined dysfunctions in commonly unelucidated pathways. Germane to 3i, the recent 
demonstration that causative dysfunction in SLE and MS could be tracked via discrete 
endophenotyes15 emphasises the value of associating specific genes and pathways to specific 
endophenotypes. Likewise, relative proportions of murine splenic cell types have proved to 
be powerful indicators of autoimmune dysregulation47. Added to this, the web-based 
curation of 3i data-sets, comparing hundreds of single-gene ablations on the C57BL/6N 
background, one the most-widely used animal models, might help predict the outcomes of 
drug-mediated pathway inhibition18.  
 
The scale, throughput, and robustness of 3i were also sufficient to provide insight into the 
nature and scope of immune variation in C57BL/6N mice. For example, whereas sexual 
dimorphism of immune parameters is well established48,49, 3i established that its impacts are 
highly selective. The analysis of immune variation at scale also revealed dense correlation 
networks of immune parameters with each other and with general physiologic traits. De 
facto, such correlations impose structures constraining immune variation. Although structure 
was more evident in males, it likely exists in females but in practical terms may be masked by 
higher variability in general physiology. This notwithstanding, correlations offer insights into 
physiologic and environmental factors, e.g. diet, that may regulate specific 
immunophenotypes, and may additionally provide practical surrogate measures of immune 
status.  
 
While immune correlations and resulting structures will differ in detail across organs, strains 
and species, they provide a revised framework for viewing immune variation. For example, 
the co-ordination of immune cell subsets reflected by immunologic structure may confer on 
the immune system a critical agility to respond to diverse challenges. Thus, structure metrics 
(e.g. subset ratios versus consensus values) might usefully be included in immune-monitoring 
strategies. Supporting this, Bach2, Cog6 and Arpc1b, which were readily scored as disrupting 
correlations, are strongly associated with human disease40-42,50-52. Moreover, therapeutic 
responsiveness to checkpoint blockade was recently associated with a ratio of CD8+ T cell 
subtypes, rather than with individual subsets53. In parallel, the unanticipated density of 
correlation networks revealed by 3i makes the case for investigating their biological basis.  
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Figure Legends 
 
 
Figure 1: Variation in immune cell subset composition with sex as a contributory driver 
a. Overview of the tests performed by WTSI as part of IMPC (inner circle) and by 3i and 
WTSI as part of 3i (outer circle).  
b. Sexual dimorphism in the immune system: Population sizes as % of CD45 cells (upper 
panel); sexual dimorphism of mean values of population sizes as log2 fold change 
(middle panel, female/male); and % coefficient of variation (lower panel) of immune 
populations in SPL, BM and PB from 16-week old male and female wt C57BL/6N mice 
(n>500). Blue arrows denote cell subsets mentioned in text. Blue and orange circles in 
bottom panel denote CV values for female and male mice, respectively. Non adjusted 
p-values from two-sided Wilcoxon test. 
c. Left: Neutrophils from peripheral blood of 16-week old wt C57BL/6N mice (for females 
n=918 and for males n=913, bars represent means) Right: Hardy fractions A and C from 
the bone marrow of 16-week old WT C57BL/6N mice (for females n=308, for males 
n=315, bar represents mean) 
d. PCA of cell type frequencies from four tissues (SPL, MLN, BM, PB), 60 subsets, and 451 
mice; colour denotes sex.  
 
Figure 2: Correlations exist between immune parameters 
a. Heat map represents Pearson correlations of 46 splenic immune cell subsets with each 
other in wt males (n>230) as determined by flow cytometry. Dark red fields denote 
strong positive, dark blue fields strong negative correlations between frequencies of 
spleen immune cell subsets. 
b. Correlation differences between males and females. Colour denotes ∆R, the 
difference between the correlation coefficient R for SPL subsets in male and female 
wt mice. Black circumferences mark parameter pairs that are significantly sexually 
dimorphic (see Materials and Methods). Correlation coefficients for male and female 
mice were derived from data depicted in Fig 2a and Fig S2, respectively.  
 
Figure 3: Correlations between immune and non-immune parameters form a sex-specific 
network of interactions 
Correlations with a Pearson R-value >0.33 and p<0.001 between PBL, SPL, MLN, BM with 
haematological, clinical blood chemistry, and additional parameters (see Supplementary 
Fig 3) for males (a) and females (b). Circle colours denote organ assayed; red lines denote 
positive correlations; blue lines, negative correlations (n>180 per sex). 
 
Figure 4: 140 out of 530 genes perturb the immunophenotype  
Red, significantly different from wt; blue, not significantly different from wt; white, not 
performed; grey, insufficient data to make a call. Each cell is coloured red when at least 
one of parameters within an assay is significant. Methods for determining significance of 
parameters are parameter-specific (see Materials and Methods and 
www.immunophenotyping.org). 
 
Figure 5: Examples of genes with specific impacts on the immune system 
a. Overview of two genes that display specific immunophenotypes. Colours as in Fig 4. 
Statistical methods and sample size differ between parameters – see Materials and 
Methods and www.immunophenotype.org for specific gene/parameter combination 
of n.  
b. Vγ5 DETC in ear epidermis of wt and Nacc2–/– mice. The image represents a z-
projection of cell outlines produced by image processing in Definiens Developer XD, 
which were used for quantitative object-based image analysis: blue, Langerhans cells 
(LC); red, V5+ DETC contacting LC; green, V5+ DETC not contacting LC. Bottom: 
cumulative data for Nacc2–/– mice (n=4) versus sex-matched wt controls (for females 
n=330, for males n=340, bar represents mean). 
c. Phenotypic abnormalities in Dph6–/– mice. Fold change in immune cell subset 
proportions between Dph6–/– and wt mice across multiple tissues (Dph6–/–, n=6 for 
SPL, MLN, BM and n=14 for PBL; wt, n>500 for all parameters).  
 
Figure 6: Examples of genes that impact upon the immune system and physiology 
a. Overview of two genes that exhibit broad immunophenotypes. Colours as in Fig 4. 
Statistical methods and sample size differ between parameters – see Materials and 
Methods and www.immunophenotype.org for specific gene/parameter combination 
of n.  
b. Phenotypic abnormalities PBL in Duoxa2–/– mice . Relative PBL cell subset frequencies 
for Duoxa2–/– (n=11) versus wt mice (n>450 per sex for all parameters). Dark and light 
blue denote wt males and females; red and orange denote Duoxa2–/– males and 
females. 
c. Effector cell subsets in Bach2–/– mice. Fold-change in SPL cell subset composition in 
mutant mice (n=6) versus wt controls (n=76). Yellow represents significant cellular 
phenotypes not previously reported, as detected by reference range; dark blue 
represents significant cellular phenotypes previously reported; light blue represents 
non-significant differences. KLRG1+CD4- NK cells: 10-fold increase, p=1.1x10-9; 
reference range combined with Fisher’s exact test). 
d. Cytotoxic T lymphocytes in Bach2–/– mice (n=4) compared to wt controls (212 female 
and 208 male): grey points represent individual wt mice; red circles represent 
individual Bach2–/– mice. 
e. DSS colitis in Bach2–/– mice (n=4) compared to wt controls (n=481 female and 
n=315male): grey points represent individual wt mice; white circles represent wt 
mean values; blue circles represent individual Bach2–/– mice. 
 
Figure 7: Genes affecting baseline immunophenotypes and challenge responses  
a. Effected parameters and Pubmed citations per gene. Each bubble represents one 
gene; size represents the number of immune flow phenotypes detected for that gene; 
colour represents the extent to which each gene has been reported on, determined 
by number of Pubmed citations, as of October 2018. Numbers denote the numbers of 
genes in quadrants of the figure. 
b. Tolerance to LOF mutations in human orthologs of 3i genes. Left-hand panel: LOF 
tolerance scores derived from GnomAD for human orthologs of: 3i genes without hits 
(blue, n=334); 3i genes with hits OMIM/GWAS genes excluded (purple, n=77), and for 
all GnomAD genes (red, n=16037). A score of 0 denotes complete intolerance; a score 
of 2 complete tolerance to loss of function. Wilcoxon test: purple versus red p=0.010; 
purple versus blue p=0.009. Deciles of all genes marked with vertical grey broken lines. 
Middle panel: Genes tested in heterozygotes. 3i genes without hits (blue, n=109), 3i 
genes with hits (green, n=31), 3i genes with hits OMIM/GWAS genes excluded (purple, 
n=19). Wilcoxon test: purple versus blue p=0.0029; green versus blue p=0.003. Right-
hand panel: Human orthologs of all 3i genes without hits (blue, n=334) versus genes 
with hits in steady state flow cytometry phenotypes but without challenge hits 
(orange, n=34); orange versus blue p=0.014, Wilcoxon test. 
c. Relationship between immune phenotypes and non-immune phenotypes. Each 
bubble represents one gene; size represents the number of immune flow phenotypes 
detected for that gene; colour indicates non-immune phenotype. Genes with any 
immune hit and a non-immune phenotype (orange bubbles among bubbles in top and 
right bottom quadrants) versus not hit genes (orange bubbles among bubbles in left 
bottom quadrant); p=0.000072, Fisher exact test. Genes with baseline phenotype 
change and a non-immune phenotype (orange bubbles among bubbles in right bottom 
quadrant) versus not hit genes (orange bubbles among bubbles in left quadrants); p= 
p=0.00021, Fisher exact test. 
 
Figure 8: Phenodeviants preserve or break immunological structures.  
a. Schematic illustrating the concept of structural perturbation. The yellow and green 
genes are theoretical hits in both correlated parameters (Pearson’s correlation), and 
exist as an exaggeration of the normal relationship that exists at steady state (grey 
dots represent wt mice). The pink gene is also a hit in both parameters, but breaks the 
correlation by falling outside the blue corridor that represents a 95% prediction 
confidence interval around the correlation line.  
b. Examples of genes that preserve or disrupt immunological structure. Plotted are data 
frequencies of SPL subsets (indicated on x- and y-axes) as determined by flow 
cytometry. Data from mutant lines with phenotypes are highlighted in different 
colours; large dots represent the x/y centroid (mean) values, small dots represent data 
points for each mouse. Grey data points represent wt mice and mutant mice that are 
comparable to wt mice for both parameters shown. n=4 for Arhgef1–/–, n=5 for 
Arpc1b–/– , n=5 for Gmds–/– , n=4 for Pclaf–/–. 
c. Genes differ in their capacity to break or preserve relationships. Stated in red font are 
the number of correlations that each cited gene disrupts and in blue font the residual 
number of correlations that each cited gene preserves, the total being all correlations 
contributed to by the steady-state parameters that the cited gene affects. These are 
represented as percentages in the left-hand graph (correlations across organs) and 
right-hand graph (correlations within the same organ). Only genes affecting 
parameters which contribute to >10 correlations are depicted. Statistical significance 
was determined by two-sided Fisher’s exact test in comparison to the data set average 
(dotted line). Number of correlations above bars, *p<0.05, **p<0.01, ***p<0.001. 
d. Examples of genes that either preserve or disrupt many correlations. Plotted are 
parameters (colour-coded according to cell lineage) in BM, SPL, MLN, and PBL, and 
the correlations that link them in wt mice (left panel, grey lines) or in Dph6–/– mice 
(middle) or Cog6–/– mice (right), in which cases blue and red lines denote 
correlations that are preserved or broken, respectively. 
e. Comparison of correlation breaking in genes that score in non-immune tests and 
immune tests versus genes that have hits only in immune parameters (Probit 
regression, p=2.74*10-11; p=7.45*10-7 when controlling for unequal numbers of 
correlations per gene; p=0.007 when allowing for any dependencies of correlations 
within a gene by using cluster-robust standard errors). Numbers of correlations 
above bars. 
f. Comparison of correlation breaking in genes that score in challenge assays and 
steady-state immune tests versus genes that have hits only in steady-state immune 
parameters (Probit regression, p=3.95*10-18; p=9.10*10-16 when controlling for 
unequal numbers of correlations per gene; p=0.021 when allowing for any 
dependencies of correlations within a gene by using cluster-robust standard errors). 
Numbers of correlations above bars. Separate contributions of non-immune and 
challenge phenotypes: p= 1.56*10-6 for non-immune controlling for challenge; 
p=2.93*10-13 for challenge controlling for non-immune. 
 
  
 Materials and Methods 
 
Contact for Reagent and Resource Sharing 
All reagents used are listed in Supplementary Table 5. For additional information about 
reagents and resources, contact Adrian Hayday at adrian.hayday@kcl.ac.uk. 
 
Experimental design 
All assays relied on the fastidious application to cells and tissues of intensively piloted, robust, 
optimised Standard Operating Procedures (SOPs) employing high-resolution, quantitative 
protocols, whose high reproducibility was monitored over time (e.g. Supplementary Fig 1f). 
 
Mice were randomly allocated to the experimental groups (wt versus ko) by Mendelian 
inheritance. The experimental unit in the study was the individual mouse. For the majority of 
tests, operators were blinded with regard to the genetic identities of mice. Further detailed 
experimental design information is captured by a standardized ontology as described19, and 
is available from the IMPC portal (www.mousephenotype.org). The steady-state screens 
integrated within the HTS followed a multi-batch design, in which a baseline set of control 
data was constantly collected by phenotyping wt mice of both sexes along with mutant mice 
at least once per week. As soon as mutant mice from the breeding colonies reached 
appropriate ages, they were issued to the pipeline until sufficient number of males and 
females of each genotype were assessed. In this way, animals from each mutant strain were 
tested on two to five days, interspersed throughout experiment duration, rather than within 
one batch. For advantages and robustness of such design in an HTS see 21,54-56. The challenge 
screens implemented a parallel group study design. 
 
Compliant with HTS practice, the numbers of mice examined in each assay were dictated by 
costs, logistics, and power, with bespoke statistical tests (see below) applied to identify genes 
(so-called “hits”) perturbing defined components of the immune system. Two to seven 
homozygote mice of each sex per mutant line were assessed per test. If no homozygotes were 
obtained from >28 offspring of heterozygote intercrosses, the line was deemed homozygous 
lethal. Similarly, if <13% of the pups resulting from intercrossing were homozygous, the line 
was judged as being homozygous subviable. In either case, heterozygotes were phenotyped. 
The numbers and sex of animals tested per genotype and assay are summarized in 
Supplementary Table 3. 
 
Ethical compliance 
Mouse use in this study was justified based on their facilitating a large variety of phenotypic 
tests to be carried out on a sufficient number of individuals in a controlled environment. The 
care and use of mice in the study was conducted in accordance with UK Home Office 
regulations, UK Animals (Scientific Procedures) Act of 2013 under two UK Home Office 
licenses which approved this work (80/2076 and 80/2485) which were reviewed regularly by 
the WTSI Animal Welfare and Ethical Review Board.  
 
All efforts were made to minimize suffering by considerate housing and husbandry, the 
details of which are available at the IMPC portal: http://www.mousephenotype.org/about-
impc/arrive-guidelines. Animal welfare was assessed routinely for all mice involved. Adult 
mice were killed by terminal anaesthesia followed by exsanguination, and death was 
confirmed by either cervical dislocation or cessation of circulation. 
 
Animals 
Mice were maintained in a specific pathogen-free unit under a 12-hour light, 12-hour dark 
cycle with water and food ad libitum (Mouse Breeders Diet (LabDiets 5021-3, IPS, Richmond, 
USA), unless stated otherwise. Mice where housed in Tecniplast Sealsafe 1284L (overall 
dimensions of caging (L × W × H): 365 × 207 × 140 mm; floor area = 530 cm2) at a density of 
3-5 animals per cage, and provided with a sterilized aspen bedding substrate and cardboard 
tubes and nestlets for environmental enrichment.  
 
Mutant mouse production 
Mice carrying knockout first conditional-ready alleles were generated on a C57BL/6N 
background using the EUCOMM/KOMP Embryonic Stem (ES) cell resource, with ES quality 
control and molecular characterization of mutant mouse strains performed as described 
previously 57. Upon completion of phenotyping, genotyping was repeated and data were only 
accepted from mice for which the second genotype was concordant with the original. The 
knock-in first strategy first generates mice that still possess the full sequence of the targeted 
gene, interrupted in a crucial exon by the inserted cassette. These tm1a alleles result in 
functional knockout lines in most cases, but can carry residual expression of the targeted 
gene. These tm1a alleles can be converted into unequivocal full knockout tm1b alleles by 
excising the inserted cassette with the targeted essential exon. Details of alleles used can be 
found in Skarnes et al19. All lines are available from www.knockoutmouse.org or 
mouseinterest@sanger.ac.uk.  
 
Non-immune phenotyping 
Non-immune phenotyping (summarized in Supplementary Fig 1a) was conducted as 
described 21. Screening for phenotypes in Citrobacter infection was replaced by the 3i 
challenges. 
 
Immunological steady-state phenotyping 
Tests conducted in the steady-state (PBL, SPL, MLN, BM, ear epidermis, antinuclear 
antibodies, cytotoxic T lymphocytes function) were conducted on the same 16-week-old mice 
that were subject to broad non-immunological phenotyping procedures21. Non-fasted mice 
were terminally anaesthetised using Ketamine (100 mg/kg)/Xylazine (10 mg/kg) injection. 
Organs were harvested and either analysed directly (PBL) or shipped in HBSS at 4C for 
analysis on the same day off-site. Readouts of the respective tests and numbers of mice used 
are summarized in Supplementary Fig 1 and Supplementary Table 3.  
 
Single cell preparation of immune cells from spleen 
After removing the fat, spleens were transferred into Miltenyi C-tubes with 3 ml of enzyme 
buffer (PBS Ca2+/Mg2+, 2% FCS (v/v), 10 mM HEPES, Collagenase (1 mg/ml), and DNAse 
(0.1 mg/ml). Samples were then processed using a Miltenyi Gentle MACS dissociator (SPL 
program 01) and incubated at 37°C for 30 minutes. After the incubation, samples were 
processed again in the Miltenyi Gentle MACS dissociator (SPL program 02) and the enzyme 
reaction was stopped adding 300 μl of stop buffer (PBS, 0.1 M EDTA). Samples were filtered 
through 30 μm filters and centrifuged for 5 minutes at 400 x g at 8°C. The pellet was 
resuspended in FACS buffer (PBS, Ca2-/Mg2-, 0.5% FCS, EDTA 2mM), incubated for 60 seconds 
in RBC lysis buffer and then washed with FACS buffer. Samples were transferred to 96-well V 
bottom plates and incubated in 50 μl of RBC lysis buffer (eBioscience) for 1 minute prior to 
antibody staining.  
 
Single cell preparation of immune cells from mesenteric lymph nodes (MLN) 
After removing the fat, MLN were transferred into 1.7 ml microfuge tubes with 200 μl of 
buffer (PBS Ca2+/Mg2+, 2% FCS (v/v), 10 mM HEPES) and ruptured using small plastic pestles. 
400 μl enzyme buffer (PBS Ca2+/Mg2+, 2% FCS (v/v), 10 mM HEPES), Collagenase (1 mg/ml), 
and DNAse (0.1 mg/ml) were and samples were incubated for 15 minutes at 37°C. The 
reaction was stopped by adding 60 μl stop buffer (PBS 0.1 M EDTA) and samples filtered 
through 50 μm filters and centrifuged for 5 minutes at 400 x g at 8°C. The cell pellet was 
resuspended in FACS buffer (PBS Ca2-/Mg2-, 0.5% FCS, EDTA 2 mM) and transferred to 96-well 
V bottom plates for antibody staining. 
 
Single cell preparation of immune cells from bone marrow (BM) 
The tibia was cleared of muscle tissue and cut below the knee and above the ankle. The open 
bone was placed into a cut pipette tip placed into a microfuge tube, thereby keeping the bone 
away from the bottom of the tube and allowing the bone marrow to be centrifuged out of 
the bone at 1000  g for 1 minute. The bone was discarded and the pellet resuspended in 
50 μl RBC lysis buffer at room temperature for 1 minute. Cells were washed in 200 μl FACS 
buffer and again centrifuged at 1000  g for 1 minute. Cells were resuspended in 400 μl FACS 
buffer and transferred to 96-well V bottom plates for antibody staining. 
 
Blood preparation 
Blood was collected into EDTA coated tubes (peripheral blood leukocytes assay) via the retro-
orbital sinus. Whole blood for peripheral blood leukocyte assays was stained with two titrated 
cocktails of antibodies (Supplementary Table 1). Using the white blood cell count obtained 
from the haematological analysis, absolute cell counts were derived for each population and 
reported as cells/µl. 
 
Immunophenotyping by flow cytometry  
Single cell suspensions were incubated with Fc-block for 10 minutes at room temperature, 
washed four times, first with FACS buffer and then with PBS, and then incubated with 
live/dead ZiR dye (BioLegend) for 10 minutes at room temperature. Samples were washed 
again with FACS buffer and incubated with antibody cocktails (see Supplementary Table 1) at 
4°C for 20 minutes. Samples were washed twice with FACS buffer and measured on a BD 
Fortessa X-20 equipped with 405 nm, 488 nm 561 nm and 644 nm lasers (see Supplementary 
Table 1). Full details of instrument setup are available at www.immunophenotyping.org. 
Panels were modified slightly in summer 2014 in order to better correspond to the IMPC 
panels (T cell panel: 9th June 2014, B cell panel: 15th September 2014). Data before and after 
this data split were analysed separately. Data were analysed with FACSDiva and Flowjo 
software. FCS files are available from flowrepository.org. 
 
Flow cytometry quantification (SPL, MLN and BM) 
Additionally to the manual gating performed at the time of data acquisition, collected flow 
cytometry data for SPL, MLN and BM were gated computationally using flowClean, UFO, and 
flowDensity22,58. FlowClean was used to perform acquisition-based quality checking to 
remove anomalous events. Files with fewer than 20,000 events were then removed from 
further analysis. UFO was used to identify outlier samples (e.g., batch effects). FlowDensity 
was used to enumerate cell populations by automating a predefined gating approach using 
sequential, supervised bivariate gating analysis to set the best cut-off for an individual marker 
using characteristics of the density distribution. The parameters for each individual cell 
population were pre-defined once for all files. The automated analysis data was validated 
against matched manually analysed data. Gating strategies are outlined in Supplementary Fig 
1b and in Supplementary Fig 6). Assessment of absolute cell counts were not compatible with 
the high-throughput workflow employed in the study for SPL, MLN and BM. All cell subset 
frequencies are presented as a percentages of a relevant parent populations. 
 
Ear epidermis immunophenotyping 
Epidermal sheets from mouse ears were treated with hair removal cream (Nair) for 4 minutes 
at room temperature. After removing the cream by extensive washing in PBS, ears were split 
into dorsal and ventral sides and incubated dermal side down for 35 minutes at 37°C in 0.5 M 
ammonium thiocyanate (Sigma-Aldrich). Epidermal sheets were gently peeled from the 
dermis in PBS, and fixed in cold acetone for 20 minutes at -20°C. After washing in PBS, 
epidermal sheets were incubated for 1 hour at room temperature with 5% (wt/vol) FCS in PBS 
and were stained for 1 hour at 37°C with Vγ5 TCR-FITC (clone 536; BD), MHCII-AF647 (I-A/IE; 
BioLegend) and CD45-eFluor450 (eBioscience). Epidermal sheets were washed extensively in 
PBS and mounted on slides with ProLong Gold antifade medium (Life Signalling Technologies). 
Leica SP2 or SP5 confocal microscopes equipped with 40 x 1.25 NA oil immersion lens and 
405 nm, 488 nm and 633 nm lasers were used to record 1024 x 1024 pixel confocal z-stacks 
with Leica Acquisition Software. The confocal records were processed and quantified with 
Definiens Developer XDR software using a custom-made automated protocol where images 
were smoothed with a sliding window Gaussian pixel filter, segmented by an automated 
Otsu’s method and then filtered based on object size and morphology parameters to detect 
cells in each fluorescence channel. Further, in order to quantify the number and length of 
dendrites, the detected cells were skeletonised in 3D to determine the points where 
dendrites start to branch out of the cell body. Mean of 3 vision fields was used for 
quantification. 
 
Antinuclear Antibody Immunophenotyping 
Murine serum samples were obtained and stored at -20°C prior to analysis (after dilution 
1:100 in PBS) by incubating on commercially-sourced substrate slides (A. Menarini Diagnostics 
Ltd.) coated with HEp-2 cells for 30 minutes at room temperature in a humidifying tray. 
Samples were removed and slides were washed twice with PBS for 5 minutes and once with 
water for 5 seconds. Slides were incubated with FITC-conjugated goat anti-mouse IgG, diluted 
1:500 and incubated for 20 minutes at room temperature in a humidifying tray in the dark. 
The secondary antibody was removed and slides washed twice with PBS for 5 minutes and 
once with water for 5 seconds, both in the dark. Slides were mounted in medium and stored 
at 4°C prior to imaging for 400 ms at 20 x magnification in the GFP channel on a Nikon wide-
field TE2000U Microscope or a Deltavision Elite widefield system based on an Olympus 
microscope. Images were subject to multi-parametric analysis in Fiji. Samples were scored 
from 0-4 according to intensity based on control samples and commercially sourced FITC QC 
beads. Samples scored ≥2 were marked as ANA positive. All sera flagged by automated image 
analysis as putative positives vis-à-vis a contemporaneous standard were manually cross-
checked for bona fide nuclear localization before scoring. 
 
Cytotoxic T Lymphocyte Immunophenotyping 
Mouse splenocytes were isolated using 70 M cell strainers (BD Plastipak) and cultured in T 
cell media (TCM: 500 ml RPMI, 500 μl B-ME, 5 ml NaPyr, 5 ml pen/strep, 5 ml L-glut, 50 ml 
10% heat inactivated FCS and 100 μl IL-2) on 6-well plates pre-coated with 0.5 μg/ml anti-
CD3 antibody and 1 μg/ml anti-CD28 antibody (1.7106 cells/well) for 48 hours. Plates were 
washed and cells where cultured for a further 8 days with daily passage prior CTL assay. 
 
Cytotoxicity assays were performed using a CytoTox96 Non-Radioactive Cytotoxicity Assay kit 
(Promega UK Ltd). Cells were washed and re-suspended in killing assay media (KAM: 500 ml 
RPMI-phenol red, 10 ml 10% heat inactivated FCS and 5ml pen/strep), with CTLs at a 
concentration of 0.1 × 106 and P815 target cells at a concentration of 0.1 × 106. Purified 
hamster anti-mouse CD3 antibody was added to P815 target cells.  
 
P815 cells were added to a serial dilution of CTL samples and incubated for 3 hours. Lysis 
buffer (Promega UK Ltd.) was added to control samples and incubated for 45 minutes. 
Supernatants were harvested and substrate mix (Promega UK Ltd) was added prior to a 30-
minute incubation in the dark. Stop solution (Promega Corporation UK Ltd) was added to halt 
the reaction and results acquired using a spectrophotometer (VersaMax, molecular devices).  
 
Flow cytometric analysis was performed to assess the percentage of CD4+ and CD8+ cells 
within the cell culture. The cell suspension was washed in FACS buffer and the cell pellet re-
suspended in a staining master mix (FACS buffer solution + 1:200 anti-CD8 APC and 1:200 
anti-CD4 PE). Tubes were then incubated in the dark for 7 minutes at room temperature 
before the antibody was washed off and cells resuspended in FACS buffer. Results were 
acquired on a FACS Calibur machine and analysed using FlowJo 10 software.  
 
Challenge screens 
Challenge screens were conducted on separate cohorts of mice from the same breeding 
colony used for the steady-state screens. 
 
DSS colitis challenge 
Colitis was induced by adding 1.5% (w/v) DSS (Affymetrix, Inc.) to drinking water for 7 days, 
followed by 3 days with regular drinking water, in animals aged between 5 and 18 weeks 
(mean age 9 weeks). Mice were weighed every day and culled if weight loss reached 20% of 
starting weight.  
 
For histological assessment of intestinal inflammation, mice were sacrificed at day 10 by 
cervical dislocation, and samples from mid and distal colon taken. Tissue sections were fixed 
in buffered 10% formalin; paraffin-embedded; cut; and stained with haematoxylin and eosin. 
Colon histopathology was blind-graded semi-quantitatively on a scale from zero to three, for 
four criteria: (1) degree of epithelial hyperplasia/damage and goblet cell depletion, (2) 
leukocyte infiltration in lamina propria, (3) area of tissue affected, and (4) presence of markers 
of severe inflammation, including crypt abscesses, submucosal inflammation, and oedema. 
Scores for individual criteria were added for an overall inflammation score of between zero 
and twelve for each sample. Scores from mid and distal colon were then averaged to obtain 
inflammation scores for each mouse colon.  
 
Salmonella typhimurium challenge 
Groups of 8 mutant and 8 C57BL/6N wild type mice were challenged intravenously with 
5 x 105 colony forming units (cfu) Salmonella typhimurium M525 :: TetC, (Fragment C of 
tetanus toxin, to act as an antigen for subsequent antibody quantification), and followed for 
28 days. On day 14 post-infection (pi), four mutant and four wt mice were sacrificed by 
cervical dislocation and organs (spleen, liver and caecum) removed. A small piece of spleen 
and liver was fixed in 4% formalin and then later processed to paraffin blocks as an infected 
tissue biobank. The rest of the organs were weighed then homogenized, serially diluted and 
plated to determine viable bacterial load. At day 28 pi, the remaining four mice were culled 
by cardiac puncture under terminal anesthesia and organs removed and processed, as above. 
The blood was allowed to clot, then centrifuged, serum collected and used to detect TetC 
antigen specific antibodies by enzyme-linked immunosorbent assay (ELISA). Mice were 
weighed and monitored daily for signs of pathophysiology. 
 
Influenza challenge 
Mutant and wt mice (5-21 weeks of age) were lightly anesthetised and intranasally inoculated 
with 171 or 227 p.f.u. of A/X-31 (H3N2) influenza in 50 μl of sterile PBS. Mouse weight was 
recorded daily and the percent reduction was calculated from their weight on day 0. Mice 
were sacrificed by cervical dislocation on day 10 pi, and the area under the curve from day 0 
to 9 pi was calculated. Mice exceeding 25% total weight loss were culled in accordance with 
UK Home Office guidelines. 
 
Trichuris muris challenge 
The Edinburgh (E) strain of Trichuris muris was used in all experiments. Female mice (6-12 
weeks old) were orally infected with 400 embryonated eggs. Mice were culled by cervical 
dislocation at day 32 pi, blood was collected by cardiac puncture for serum recovery, and 
caecum/proximal colon was dissected to inspect for worm presence by stereomicroscope. 
Levels of parasite-specific serum IgG1 and IgG2a Ab were by ELISA: briefly, ELISA plates were 
coated with T. muris excretory/secretory (E/S) antigen at 5 g/ml. Serum was diluted 1/40, 
and parasite-specific IgG1, IgG2a and IgE detected with biotinylated anti-mouse IgG1 (Biorad), 
biotinylated anti-mouse IgG2a (BD PharMingen), and anti-mouse IgE (BioLegend), 
respectively. To generate T. muris E/S antigen, live adult worms were incubated at 37°C for 
24 hours in RPMI-1640 medium (Gibco, UK) supplemented with 500 U/ml penicillin, 
500 g/ml streptomycin and 2 mM L-glutamine (all Gibco, UK). Supernatants were removed, 
centrifuged at 2000 x g for 15 minutes, filtered through a 0.22 m filter (Millipore, UK), 
concentrated using a 10 kD molecular weight cut off Centriprep concentrator (Amicon, UK) 
and dialysed against PBS over a 24-hour period. The supernatant was subsequently filtered 
again and protein concentration determined before use. 
 
Statistical analysis 
 Sample sizes for each experimental group are included in the figure legends and 
Supplementary Table 3. Measures were taken from distinct animals in almost all experiments. 
Exceptions are body weight, where the weight of the same animal was recorded repeatedly 
during the course of the experiment and the CTL assay, in which T cells from the same culture 
were used for different effector : target ratios. Tests for all assays are listed in Supplementary 
Table 3. Reference-range tests which require no assumptions were used for most assays. 
Adjustments for multiple comparisons were not made unless stated in test description, as 
individual comparisons were not independent (e.g. percentages for different cell types 
determined by flow cytometry are often nested and dependent on each other). Low false 
positive rates were instead ensured by using conservative reference range cut-offs and 
monitoring false positive rates by simulation (Supplementary Fig 4). All tests used were two-
sided. Co-variates were included in the analysis indirectly, by dividing animals into sex-specific 
groups or matching ko and wt by assay date/weight/age (MMR analysis described below) and 
in the analysis presented in figures 8e and 8f where covariates tested are described in the 
text. A description of statistical parameters is included into the figure legends. Effect sizes are 
given when fold change between sexes was analysed. All significant calls and borderline 
candidates were manually reviewed by biological experts. 
 
Experimental batch effects were minimised by the experimental design, the statistical 
analysis and by expert review. Experimental set-up: Mice were phenotyped on at least two 
different days and typically three to four different days. Statistical analysis: Stringent 
reference range hit calling required >60% of samples to be in the upper 2.5% or lower 2.5% 
of the wt distribution. The influence of temporal drift in flowcytometric data was minimized 
by using as controls only the 70 wt mice that were closest in time for any given parameter. 
Reference ranges have been shown by the WTSI team to be stable for >60 mice. Expert 
review: Experts reviewed all hits and borderline candidates and excluded candidates that 
suffered from batch effects despite the measures taken above.  
 
Coefficient of variation (CV) was estimated as a ratio of the standard deviation of the wt 
population to its mean (for both sexes together, unless indicated otherwise). Note that since 
a data-set is expressed as frequency of parent, it is bound and CV estimates are less accurate 
close to the boundary. 
 
Sexual dimorphism 
Significance of sex as a source of variation in wt animals was tested in a mixed model (sex as 
explanatory variable, assay date as a random effect) by examining the contribution of sex to 
the model and whether the variance was homogeneous between sexes59. The effect of 
multiple testing was managed with Bonferroni correction to control the family-wise error rate 
to 5%. For Principal Component Analysis and Linear discriminant analysis (LDA), only wt 
samples with a complete set of flow parameters were used. Data was scaled. Accuracy of 
classification by sex in LDA was checked with leave-one-out cross-validation. 
 
Estimation of false positive rates 
A mutant mouse line was mimicked by randomly selecting N wt animals (N depending on the 
screen) and assessed whether it would be called a hit using the RR approach. To reflect the 
data structure and address the potentially confounding batch effect of test days, the number 
of experimental days from which animals were drawn and their sex was set according to the 
distributions observed across all tested mutant lines. For example, in the lab, bone marrow 
was collected on five different days in 36% of mouse strains; in 38% on four different dates; 
in 11% from three different days, etc. When strains were tested on four assay days, in 78% of 
cases females were tested on two days, etc. The same data structure was imposed on the 
draws for the false positive rates. Thereupon, the same rubric used for calling hits from real 
data was applied, except that the expert data review step (see above) was replaced by 
filtering out samples from the days when the median of wt animals and non-significant 
mutant strain samples was further than two median absolute deviations (MADs) from the 
overall median in wt animals. 10,000 draws were performed for each parameter to determine 
the rate at which false positives would occur. 
 
Correlation analysis 
Pearson correlations between parameters in the flow cytometry screens as well as between 
the flow cytometry screens and non-immune screens were identified in wt mice for pairwise 
complete observations, accumulated throughout whole duration of the experiment. 
Correlations with parent and sister populations were excluded from the dataset. Correlations 
with R>0.33 and p<0.0001 were considered significant. 
 
Comparison of correlations between male and female mice 
R values of all significant correlations were compared with a t-test after Fisher z-
transformation. Difference in dependence between parameters between sexes (slope of 
regression line) was tested by fitting a linear regression model to correlated parameters and 
assessing significance of interaction between sex and predictor variable. P-values were 
adjusted for multiple testing with Bonferroni correction to control the family wise error rate 
to 5%. 
 
Immunological structure analysis 
Starting from parameters that were affected in a mutant strain, a list was compiled of other 
parameters with which the affected parameter was ordinarily correlated. The wt C57BL/6N 
data were then used to predict a value for the correlated parameter in the mutant strain by 
sex-specific linear regression. If ≥60% of mice for a given mutant strain had predicted values 
outside the 95% confidence interval based on the wt distribution, the mutant line was defined 
as breaking this specific parameter correlation. Note that a single perturbed parameter could 
contribute more than one correlation to the dataset. For the purpose of this analysis, it was 
assumed that all correlations were equally likely to be broken. To assess if breaking of 
correlations was correlated with other characteristics, such as a non-immune phenotype or a 
challenge phenotype, a multivariate Probit regression analysis was undertaken. The same 
analysis was also used to control for unequal numbers of correlations per gene, allowing for 
dependencies of correlations within a gene by cluster-robust standard errors and for separate 
contributions of all characteristics tested. The analysis was carried out using R, RStudio and R 
packages ggplot2, data.table, dplyr and igraph, org.Mm.eg.db and org.Hs.eg.db. 
 
GnomAD, OMIM and GWAS analyses 
If homo-and heterozygotes were analysed from the same strain, only homozygotes were 
included in this analysis. Human orthologues were based on JAX definition 
(http://www.informatics.jax.org, accessed 05.05.2016) and only 1:1 human-mouse 
orthologues were used. GnomAD scores were extracted from release 2 (gs://gnomad-
public/release/2.1/ht/constraint/constraint.ht)46. 
 
OMIM annotations were obtained on 31 May 2017, with immune-related OMIM-listed genes 
considered as those implicated in phenotypes of immunodeficiency, recurrent infections, 
autoimmunity. 
 
GWAS associations were obtained from the full NHGRI-EBI GWAS catalog database 78 on 
September 10, 2017 (file gwas_catalog_v1.0.1-associations_e89_r2017-07-31.tsv). In GWAS 
annotation, "immune-related" genes were considered as those mapping to susceptibility to 
autoimmune disease (systemic lupus erythematosus, psoriasis, rheumatoid arthritis, Sjögren 
syndrome, primary biliary cholangitis, ulcerative colitis, inflammatory bowel disease, Crohn's 
disease, multiple sclerosis, type 1 diabetes, Graves' disease, late-onset myasthenia gravis); 
immune response to virus (measured by secreted TNF-alpha); and functional units of gut 
microbiota. 
 
Gene overrepresentation analysis 
Enrichment analysis was performed with PANTHER Overrepresentation Test with the tool 
version 14.1 (Released 2019-03-12, www.pantherdb.org)60. We calculated significance of 
over- and underrepresentation of GO-slim Biological Process categories among 466/530 
genes with available GO annotation, by Fisher's Exact test and with FDR multiple testing 
correction. Only categories with more than one gene expected in our dataset and less than 
1000 genes in the mouse genome were included. 
 
 
Data and Code Availability 
 
The flow cytometry files that support the findings of this study are available from 
www.flowrepository.org with the identifiers listed below: 
3i PBMC panel 1: FR-FCM-ZYPJ 
3i PBMC panel 2: FR-FCM-ZYPK 
3i T-cell Spleen IMPC: FR-FCM-ZYX9 
3i T-cell MLN IMPC: FR-FCM-ZYXB 
3i B-cell Spleen IMPC: FR-FCM-ZYXC 
3i B-cell MLN IMPC: FR-FCM-ZYXE 
3i M-cell Spleen IMPC: FR-FCM-ZYXF 
3i M-cell MLN IMPC: FR-FCM-ZYXG 
3i P2 SPL IMPC: FR-FCM-ZYXN 
3i BM IMPC: FR-FCM-ZYXQ 
 
Vignettes showing gating of affected cell populations in KO mice and controls are available 
for all phenotypes deemed significant in this study in flow cytometry assays through 
www.mousephenotype.org (access through Associated Images on a gene page). 
Microscopy image files from ear epidermis assay, ANA assay and DSS histology are available 
from the corresponding author upon request and are submitted to 
www.mousephenotype.org (access through Associated Images on a gene page). 
All assay results on mouse and strain level that support the findings of this study are available 
through http://www.immunophenotype.org (website entirely devoted to this project) and 
www.mousephenotype.org (access via gene name). 
Figures with associated raw data are: 
1bcd, 2AB,3ab, 5bc, 6bcde, 7abc, 8cef,S1eghi, S2, S3ab, S4abcd. Supporting data is in Source 
data files and also available from https://github.com/AnnaLorenc/3i_heatmapping. 
 
Code used for initial hit calling and preprocessed per-mouse data for flow cytometry, ear 
epidermis and DSS assays are available from 
https://github.com/AnnaLorenc/3i_heatmapping. 
The PhenStat R package used for Influenza analysis is available on Bioconductor 
(www.bioconductor.org). The ImageJ macro and the Python code used to score ANA 
positivity, the Definiens Developer code to assess the ear epidermis images and the R code 
used to assess the false positive rate are available on request.  
 
Material Availability 
All mouse lines analysed in this work are available from repositories linked to the 
International Mouse Phenotyping Consortium (www.mousephenotype.org) or from WTSI 
(email mouseinterest@sanger.ac.uk). Cell lines are available upon request. 
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Supplementary	Figure	1:	Assay	overview.		
a. Overview	of	the	IMPC	tests	performed	at	Wellcome	Trust	Sanger	Institute	(WTSI)	
prior	to	the	substantial	expansion	by	3i.	
b. Flow	cytometry	screen.	Representative	MLN	data	illustrate	gating	strategy	for	T	cells,	
NKT	cells	and	NK	cells.	Subsets	of	key	populations	are	shown	in	gates	of	the	same	
colour.	Percentages	denote	percentages	of	parent	population.	Panels	can	be	found	
in	Supplementary	Table	1,	populations	are	quantitated	in	Supplementary	Table	2.	 	
c. Epidermis	screen.	Left	panel:	Maximal	intensity	projection	of	a	z-stack	2-channel	
overlay.	Pseudocolouring	scheme	was	applied	to	represent	Dendritic	Epidermal	Vγ5+	
γδ	T	Cells	(DETC)	in	red	and	MHC-II+	Langerhans	cells	(LC)	in	cyan,	scale	bar	50	μm.	
Middle	panel:	3D	quantitative	object-based	image	analysis	(Definiens	Developer	XD)	
of	DETC	that	contact	LC	(red)	versus	not	contacting	LC	(yellow),	and	LC	(cyan);	scale	
bar:	50	μm.	Right	panel:	3D	representation	of	a	DETC	rendering	in	Definiens	
Developer	from	which	parameters	such	as	dendricity	and	roundness	were	
quantitated;	scale	bar:	10	μm.	Measurements	were	performed	on	three	vision	fields	
from	the	same	slide	per	animal.		
d. ANA	screen.	Antinuclear	antibody	staining	in	Hep2	cells	using	serum	from	wt	mice	
and	different	ko	lines.	Sera	were	scored	on	a	scale	of	0	to	4.	The	images	illustrate	
that	sera	from	wt	or	specific	mutant	strains	do	not	all	score	equally.	Scores	of	<1	
were	regarded	as	negative;	scores	of	>2	as	positive.	Test	performed	once	per	
animal. 	
e. DSS	histology	screen.	Left:	Body	weight	curves	of	wt	and	Arhgef1–/–	mice	in	the	same	
experiment	(n=4[2M2F]	for	wt;	n=4[2M2f]	for	Arhgef1–/–).	Middle:	histopathology	
scores	of	wt	and	Arhgef1–/–	mice.	Symbols	denote	the	average	histopathology	score	
for	mid-	and	distal-colon	in	each	mouse,	and	horizontal	bars	represent	the	median	
across	mice	for	this	group.	Right:	representative	photomicrographs	of	H&E-stained	
colonic	sections	of	wt	and	Arhgef1–/–	mice;	scale	bar	0.2	mm.	One	mid-colon	and	one	
distal	colon	section	scored	per	animal.	
f. Longitudinal	monitoring	of	manually	analysed	flow	cytometry	data	for	quality	
controls	(QC),	illustrated	by	CD4+	T	helper	cells.	Daily	inner	quantiles	are	shaded	dark	
blue,	outer	quantiles	light	blue,	middle	line	is	daily	median.	All	individual	data	points	
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are	shown.	Temporal	QC	are	further	considered	in	Materials	and	Methods.	
g. Top	GO-slim	categories	(all	categories	with	raw	p-value	<	0.01	shown,	two-sided	
Fisher’s	exact	test)	among	466	of	genes	with	GO	annotation	in	3i	gene	set.	X	axis:	
number	of	genes	from	given	category	in	the	3i	set.	Coloured	by	ratio	of	observed	to	
expected	number	of	genes.	Red	frame:	immune-system	related	categories.	
Categories	significantly	different	from	whole	mouse	genome	at	FDR	5%	marked	with	
asterisk.	
h. Variation	in	immune	cell	subsets	(colours	denote	cell	lineages)	detected	by	flow	
cytometry	(denoted	by	size	of	circles).	Data	from	16-week	old	wt	C57BL/6N	SPL	
(n>500	for	all	parameters).	
i. Variation	 and	 sexual	 dimorphism	 in	 analyses	 of	 ear	 epidermal	 microscopy;	 CD8	
cytotoxicity;	DSS	colitis;	and	ANA.	Lower	panel:	sexual	dimorphism	of	mean	values	as	
log2	 fold	 change	 (middle	 panel,	 female/male);	 colour	 indicates	 p	 value	 (two	 tailed	
unpaired	t	test)	Upper	panel:	coefficient	of	variation;	colour	indicates	assay.	Number	
of	wt	samples	for	each	of	the	assays	are	listed	in	Supplementary	Table	3.	
	
Supplementary	Figure	2:	Immunological	correlations	across	parameters	
Heat	map	represents	Pearson	correlations	of	46	splenic	 immune	cell	 subsets	with	each	
other	in	wt	females	(n>230	for	all	parameters)	as	determined	by	flow	cytometry.	Dark	red	
fields	denote	strong	positive,	dark	blue	fields	strong	negative	correlations.	
	
Supplementary	Figure	3:	Non-immunological	correlations	across	parameters	
Correlations	 of	 nonimmune	 parameters	 (haematological,	 clinical	 blood	 chemistry,	 and	
additional	data)	 in	males	 (a)	and	females	 (b).	Depicted	are	correlations	with	an	R-value	
>0.33	and	p<0.001;	red	lines	denote	positive	correlations;	blue	lines,	negative	correlations	
(n>780	per	sex	for	all	parameters).		
	
Supplementary	Figure	4:	False	positive	rates	are	far	below	hit	rates.		
Expected	number	of	false	positives	estimated	by	simulation	(re-sampling	of	wt	controls,	
performed	10000	times	and	adjusted	to	the	actual	number	of	performed	tests	per	
parameter)	compared	to	the	number	of	significant	phenotypes	detected	in:	(a)	PBL	
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(n>450	per	sex	for	all	parameters),	(b)	BM	(n>350	per	sex	for	all	parameters),	(c)	SPL	
(n>250	per	sex	for	all	parameters),	and	(d)	MLN	(n>250	per	sex	for	all	parameters).	
Observed	hits	depicted	in	green;	expected	false	positives	in	red.	Significance	established	
by	windowed	70	wt	mice	reference	range,	details	in	Materials	and	Methods.	
	
Supplementary	Figure	5:	140	out	of	530	genes	perturb	the	immunophenotype		
a. Hit	rate	per	assay.	
b. Venn	 diagrams	 showing	 the	 overlap	 of	 significantly	 different	 phenotypes	 between	
assays.	
	
Supplementary	Figure	6:	Flow	cytometry	gating	strategies.	Subsets	of	key	populations	are	
shown	in	gates	of	the	same	colour.	Percentages	denote	percentages	of	parent	population.	
Panels	can	be	found	in	Supplementary	Table	1,	populations	are	quantitated	in	
Supplementary	Table	2.	T	cells	from	spleen	can	be	found	in	Supplementary	Fig	1b.	
Representative	data	for:		
a. Myeloid	cells	(data	from	spleen)	
b. B	cells	(data	from	spleen)	
c. Additional	NK	subsets	(data	from	spleen)	
d. Bone	marrow		
e. T/NK	cells	(data	from	blood)	
f. B	cells/monocytes	(data	from	blood)	
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Supplementary	Tables	1-5	
	
Supplementary	Table	1	
Markers	and	fluorochromes	used	to	identify	immune	cell	populations	by	flow	cytometry	
	
Laser	 LP	Filter	 BP	filter	
Fluoro-
chrome	
SPL/MLN	
T/NK	cells	
SPL/MLN	
B	cells	
SPL/MLN	
Myeloid	
cells	
SPL	
Myeloid	/	
B	cells	
Bone	
marrow	
405	 -	 450/50	 BV421	 Klrg1	 CD23		 CD5/19/161	 CD23	 IgM	
405	 505	 525/50	 BV510	 CD5		 CD5	 CD11b	 CD11b	 CD11b	
405	 595	 610/20	 Qdot-605	 CD45	 CD45	 CD45	 	 CD45	
405	 630	 670/30	 BV650	 CD161		 CD138	 CD317	 CD161	 CD138	
405	 750	 780/60	 BV786	 CD4		 IgM	 CD11c	 CD11c	 CD3	
488	 505	 530/30	 FITC	 CD44		 CD21/35	 MHC	II	 MHC	II	 IgD	
488	 685	 710/50	 PerCP-Cy5.5	 CD62L		 IgD	 F4/80	 	 CD43	
561	 570	 585/15	 PE	 GITR		 IgG1	 CD103	 CD21/35	 BP-1	
561	 750	 780/60	 PE-Cy7	 TCRδ		 CD95	 CD86	 CD19	 B220	
640	 -	 670/14	
APC	 CD25		 	 Ly6G	 CD5	 CD24	
AF647	 	 GL7	 	 	 	
640	 690	 730/45	 AF700	 CD8α	 B220	 Ly6C	 Ly6C	 Gr1	
640	 750	 780/60	 NIR	 Live/Dead		 Live/Dead	 Live/Dead	 Live/Dead	 Live/Dead	
	
	
Laser	 LP	Filter	 BP	filter	
Fluoro-
chrome	
PBL	
T/NK	cells	
PBL	
Myeloid/	
B	cells	
405	 -	 450/50	
BV421	 CD161	 	
V450	 	 Ly6G	
405	 505	 525/50	 BV510	 CD4	 IgD	
488	 505	 530/30	 FITC	 CD44	 Ly6B	
488	 550	 575/26	 PE	 CD25	 MHC	II	
488	 600	 610/20	 PE-CF594	 CD62L	 CD19	
488	 685	 695/40	 PerCP-Cy5.5	 TCRβ	 Ly6C	
488	 755	 780/60	 PE-Cy7	 Klrg1	 CD11b	
633	 -	 660/20	 APC	 TCRδ	 CD115	
633	 710	 730/45	 AF700	 CD45	 CD45	
633	 755	 780/60	 APC-H7	 CD8α	 	
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Supplementary	Table	2:	Parameters	of	flow	cytometry	and	ear	epidermis	assays	
	
Parameter	 Cell	markers	
Spleen	and	mesenteric	lymph	node	
Total	γδ	T	cells	 TCRδ+	
CD5+	γδ	T	cells		 TCRδ+	CD5+	
Effector	γδ	T	cells	 TCRδ+	CD62L-	CD44+	
Resting	γδ	T	cells	 TCRδ+	CD62L+	
KLRG1+	γδ	T	cells	 TCRδ+	KLRG1+	
Total	αβ	T	cells	 TCRδ-	CD5+	CD4+	or	CD8+	
Total	CD4+	T	cells	 TCRδ-	CD5+	CD4+	
CD4+	T	helper	cells	 TCRδ-	CD5+	CD4+	CD25-	GITR-		
Effector	CD4+	T	helper	cells	 TCRδ-	CD5+	CD4+	CD25-	GITR-	CD62L-	CD44+	
Resting	CD4+	T	helper	cells	 TCRδ-	CD5+	CD4+	CD25-	GITR-	CD62L+	
KLRG1+	CD4+	T	helper	cells	 TCRδ-	CD5+	CD4+	CD25-	GITR-	KLRG1+	
Total	Treg	cells	 TCRδ-	CD5+	CD4+	CD25+	GITR+		
Effector	Treg	cells	 TCRδ-	CD5+	CD4+	CD25+	GITR+	CD62L-	CD44+	
Resting	Treg	cells	 TCRδ-	CD5+	CD4+	CD25+	GITR+	CD62L+	
KLRG1+	Treg	cells	 TCRδ-	CD5+	CD4+	CD25+	GITR+	KLRG1+	
Total	CD8+	T	cells	 TCRδ-	CD5+	CD8+	
Effector	CD8+	T	cells	 TCRδ-	CD5+	CD8+	CD62L-	CD44+	
Resting	CD8+	T	cells	 TCRδ-	CD5+	CD8+	CD62L+	CD44+	
Naive	CD8+	T	cells	 TCRδ-	CD5+	CD8+	CD62L+	CD44-	
KLRG1+	CD8+	T	cells	 TCRδ-	CD5+	CD8+	KLRG1+	
Total	NKT	cells	 TCRδ-	CD5+	CD161+	
Total	CD4-	NKT	cells	 TCRδ-	CD5+	CD161+	CD4-	
Effector	CD4-	NKT	cells	 TCRδ-	CD5+	CD161+	CD4-	CD62L-	
Resting	CD4-	NKT	cells	 TCRδ-	CD5+	CD161+	CD4-	CD62L+	
KLRG1+	CD4-	NKT	cells	 TCRδ-	CD5+	CD161+	CD4-	KLRG1+	
Total	CD4+	NKT	cells	 TCRδ-	CD5+	CD161+	CD4+	
Effector	CD4+	NKT	cells	 TCRδ-	CD5+	CD161+	CD4+	CD62L-	
Resting	CD4+	NKT	cells	 TCRδ-	CD5+	CD161+	CD4+	CD62L+	
KLRG1+	CD4+	NKT	cells	 TCRδ-	CD5+	CD161+	CD4+	KLRG1+	
Total	NK	cells	 TCRδ-	CD5-	CD161+	
Effector	NK	cells	 TCRδ-	CD5-	CD161+	CD62L-	
Resting	NK	cells	 TCRδ-	CD5-	CD161+	CD62L+	
KLRG1+	NK	cells	 TCRδ-	CD5-	CD161+	KLRG1+	
Plasma	cells	 CD138+	
B1a	cells	 CD138-	B220+	CD5+	
B2	cells	 CD138-	B220+	CD5-	
Follicular	B	cells	 CD138-	B220+	CD5-	GL7-	CD95-	CD21/35int	
IgMint	
Memory	B	cells	 CD138-	B220+	CD5-	GL7-	CD95-	IgG+	
Macrophages	 F4/80+	CD11bint	
Granulocytes	 F4/80-	Ly6Ghigh	CD11b+	
Eosinophils	 F4/80-	Ly6Gint	CD11b+	SSChigh	
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Monocytes	 F4/80-	Ly6G-	Ly6Chigh	CD11b+	
Plasmacytoid	DC	 F4/80-	Ly6G-	Ly6Clow/int	CD317+	
Conventional	DC	 F4/80-	Ly6G-	Ly6Clow/int	CD317-	CD11c+	MHCII+	
Conventional	CD11bhigh	DC	 F4/80-	Ly6G-	Ly6Clow/int	CD317-	CD11c+	MHCII+	
CD11bhigh	CD86low	
Conventional	CD11blow	DC	 F4/80-	Ly6G-	Ly6Clow/int	CD317-	CD11c+	MHCII+	
CD11blow	CD86high	
CD103+	conventional	CD11blow	DC	 F4/80-	Ly6G-	Ly6Clow/int	CD317-	CD11c+	MHCII+	
CD11blow	CD86high	CD103+	
	
Spleen	only	
Immature	NK	cells	 Ly6G-	CD161+	CD5-	CD11b-	Ly6C-	
Ly6C+	immature	NK	cells	 Ly6G-	CD161+	CD5-	CD11b-	Ly6C+	
Mature	NK	cells	 Ly6G-	CD161+	CD5-	CD11b+	Ly6C-	
Ly6C+	mature	NK	cells	 Ly6G-	CD161+	CD5-	CD11b+	Ly6C+	
Germinal	centre	B	cells	 CD138-	B220+	CD5-	GL7+	CD95+	
Early	germinal	centre	B	cells	 CD138-	B220+	CD5-	GL7+	CD95+	IgM+	IgG-	
Late	germinal	centre	B	cells	 CD138-	B220+	CD5-	GL7+	CD95+	IgM-	IgG+	
Marginal	zone	precursor	B	cells	 CD138-	B220+	CD5-	GL7-	CD95-	CD21/35+	
CD23-	
Marginal	zone	B	cells	 CD138-	B220+	CD5-	GL7-	CD95-	CD21/35+	
CD23+	
Transitional	1	B	cells	 CD138-	B220+	CD5-	GL7-	CD95-	CD21/35-	
CD23-	
Transitional	2	B	cells	 CD138-	B220+	CD5-	GL7-	CD95-	CD21/35-	
CD23+	
	
Blood	
Total	T	cells	 TCRβ+	or	TCRδ+	
Total	αβ	T	cells	 TCRβ+	
Total	CD4+	T	cells	 TCRβ+	CD4+	
Effector	CD4+	T	cells	 TCRβ+	CD4+	CD62L-	CD44+	
KLRG1+	CD4+	T	cells	 TCRβ+	CD4+	KLRG1+	
Total	Treg	cells	 TCRβ+	CD4+	CD25+	
Total	CD8+	T	cells	 TCRβ+	CD8+	
Effector	CD8+	T	cells	 TCRβ+	CD8+	CD62L-	CD44+	
KLRG1+	CD8+	T	cells	 TCRβ+	CD8+	KLRG1+	
Total	γδ	T	cells	 TCRδ+	
Total	NKT	cells	 TCRβ+	CD161+	
Total	NK	cells	 TCRβ-	CD161+	
KLRG1+	NK	cells	 TCRβ-	CD161+	KLRG1+	
Total	B	cells	 CD19+	
IgD+	mature	B	cells	 CD19+	IgD+	
Monocytes	 CD19-	Ly6G-	CD11b+		
Ly6C+	monocytes	 CD19-	Ly6G-	CD11b+	Ly6C+	
Ly6C-	monocytes	 CD19-	Ly6G-	CD11b+	Ly6C-	
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Neutrophils	 CD19-	Ly6G+	Ly6B+	
Eosinophils	 CD19-	Ly6B-	Ly6G-	SSChigh	CD11b+	
	
Bone	marrow	
Granulocytes	 GR+	CD43+	
T	cells	 GR-	CD3+	
Plasma	cells	 GR-	CD3-	CD138+	
Myeloid	cells	 GR-	CD3-	CD138-	CD11b+	
Total	B	cell	precursors	 GR-	CD3-	CD138-	B220+	
Pre-pro	B	cells	(Hardy	fraction	A)	 GR-	CD3-	CD138-	B220+	CD43+	BP1-	CD24-	
Pro-B	cells	(Hardy	fraction	B)	 GR-	CD3-	CD138-	B220+	CD43+	BP1-	CD24+	
Pro-B	cells	(Hardy	fraction	C)	 GR-	CD3-	CD138-	B220+	CD43+	BP1+	CD24+	
Pre-B	cells	(Hardy	fraction	D)	 GR-	CD3-	CD138-	B220+	CD43-	IgD-	IgM-	
Immature	B	cells	(Hardy	fraction	
E)	
GR-	CD3-	CD138-	B220+	CD43-	IgD-	IgM+	
Mature	B	cells	(Hardy	fraction	F)	 GR-	CD3-	CD138-	B220+	CD43-	IgD+	IgM+	
	
Ear	epidermis	
DETC	coverage	
Count	of	DETC	Vg5+	
Count	of	atypical	CD45+	cells	
Count	of	DETC	Vg5+	contacting	LC	
Count	of	DETC	Vg5+	not	contacting	LC	
Count	of	LC	
Average	volume	of	DETC	Vg5+	
Average	volume	of	atypical	CD45+	cells	
Average	volume	of	DETC	Vg5+	contacting	LC	
Average	volume	of	DETC	Vg5+	not	contacting	LC	
Average	volume	of	LC	
Average	roundness	of	DETC	Vg5+	
Average	roundness	of	atypical	CD45+	cells	
Average	roundness	of	DETC	Vg5+	contacting	LC	
Average	roundness	of	DETC	Vg5+	not	contacting	LC	
Average	roundness	of	LC	
Average	number	of	branches	on	DETC	Vg5+	
Average	number	of	branches	on	DETC	Vg5+	contacting	LC	
Average	number	of	branches	on	DETC	Vg5+	not	contacting	LC	
Average	number	of	branches	on	LC	
Average	branch	length	of	on	DETC	Vg5+	
Average	branch	length	of	on	DETC	Vg5+	contacting	LC	
Average	branch	length	of	on	DETC	Vg5+	not	contacting	LC	
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Supplementary	Table	3:	Summary	of	statistical	procedures	per	assay	and	readout	
	
Assay	 Readouts	 Statistical	test	 Choice	of	
controls	
Successfully	
phenotyped	
strains/mice	
Ear	
epidermis	
(2F,	2M)	
Number	of	cells	
and	morphological	
parameters	
recorded	by	3D	
confocal	analysis	
and	analysed	by	an	
automated	script	
using	Definiens	
developer	
software	
Mutant	samples	were	
considered	phenodeviant	
when	falling	into	the	
lower	or	upper	2.5	
percentiles	of	the	wild	
type	distribution	of	their	
respective	sex.	A	mutant	
line	was	considered	
phenodeviant	when	≥60%	
of	samples	across	sexes	
(3/4	or	3/3)	fell	outside	
their	respective	reference	
range.		
all	wt	data,	
sex-
matched	
	
496	genes	
499	strains	
2066	ko	
mice		
728	wt	mice	
	
Cytotoxic	
T	cell	lysis		
(2F,	2M)	
Percentage	of	
target	cell	lysis	
recorded	relative	
to	a	positive	
control	(detergent)	
As	for	ear	epidermis.	A	
sample	was	considered	
outside	the	reference	
range	if	three	consecutive	
points	in	the	
target:effector	ratio	fell	
outside	the	reference	
range	for	this	ratio.	
all	wt	data,	
sex-
matched	
263	genes	
265	strains	
1130	ko	
mice		
566	wt	mice	
	
Blood		
(7F,	7M)	
Frequencies/cell	
numbers	of	cell	
populations	
recorded	by	flow	
cytometry.	
Frequencies	are	
reported	as	a	
percentage	of	
parental	
population,	
absolute	numbers	
are	calculated	
using	white	blood	
cell	counts	from	
haematology	data.	
As	for	ear	epidermis,	but	
owing	to	the	larger	
sample	size,	
phenodeviants	were	also	
identified	within	each	sex	
separately.*	
all	wt	data,	
sex-
matched	
530	genes	
533	strains		
7010	ko	
mice	2652	
wt	mice	
	
Spleen/	
MLN/BM	
(3F,	3M)	
Frequencies	of	cell	
populations	
recorded	by	flow	
cytometry.	
As	for	ear	epidermis.	A	
mutant	line	was	
considered	phenodeviant	
when	≥60%	of	samples	
70	sex	
matched	
wt	samples	
that	were	
Spleen:	
517	genes	
520	strains	
3169	ko	mi.	
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Frequencies	are	
reported	as	a	
percentage	of	
parental	
population	or	as	
percentage	of	
CD45+,	live,	single	
cells.	
across	sexes	(6/6,	5/6,	
4/6,	3/5,	3/4	or	3/3)	fell	
outside	their	respective	
reference	range.	
closest	in	
time	to	the	
mutant	
sample	
assessed.		
947	wt	mice	
	
MLN:	
508	genes	
511	strains	
2986	ko	mi.	
858	wt	mice	
	
Bone	
marrow:	
479	genes	
482	strains	
2622	ko	mi.	
795	wt	mice	
DSS	
histology	
and	
weight	
data	(2F,	
2M	or	4F)	
A)	Histological	
scoring	of	gut	
sections	
B)	Percentage	of	
reduction	in	body	
weight	compared	
to	the	start	of	the	
experiment.	
As	for	ear	epidermis	 sex-
matched	
wt	data,	70	
individuals	
closest	in	
starting	
weight	(A)	
or	age	(B)	
489	genes	
492	strains	
2001	ko	
mice	
868	wt	mice	
	
Salmonella	
bacterial	
burden	
and	serum	
antibodies	
(4F,	4M)	
A)	Colony	forming	
units	(CFU)	of	
bacteria	cultured	
on	LB	agar	isolated	
from	spleen	and	
liver	homogenates		
B)	Titers	of	
antigen-specific	
antibodies	in	
serum	measured	
by	ELISA	
Hits	were	identified	by	a	
Mann-Whitney-U	test	
with	a	p-value	cut-off	of	
0.05	in	comparison	to	
concurrent	wt	controls,	
combining	data	from	male	
and	female	mice.	
Significant	lines	were	
retested	with	a	second	
cohort.	A	final	call	was	
made	on	the	combined	
data	from	both	
experiments.		
concurrent	
wt	controls	
516	genes	
518	strains	
4133	ko	
mice	
1723	wt	
mice	
Influenza	
weight	
data:		
(3F,	3M)	
Percentage	of	
reduction	in	body	
weight	compared	
to	the	start	of	the	
experiment.	
Hits	were	identified	by	
fitting	a	robust	mixed	
model	(corresponding	to	
two-way	Anova)	with	a	p-
value	cut-off	of	0.0001,	in	
comparison	to	concurrent	
wt	controls,	taking	into	
account	sex	and	
genotype,	using	the	R	
package	Phenstat61.	
Residuals	were	assumed	
concurrent	
wt	controls	
489	genes	
490	strains	
3033	ko	
mice	
1054	wt	
mice	
	 10	
to	be	normally	
distributed.		
ANA		
(3F,	3M)		
Scores	for	ANA	
positivity	assessed	
by	microscopy	and	
analysed	using	a	
Python	script.	
Scores	from	0	to	
1.5	were	
considered	
negative;	scores	of	
2-	4	positive.		
Hits	were	identified	by	
Fisher’s	exact	test	with	a	
p-value	cut-off	of	0.01,	
comparing	the	frequency	
of	positive	samples	in	
mutant	and	wt		
wt	animals	
from	the	
contempor-
aneous	3	
months’	
period	
518	genes	
520	strains	
3286	ko	
mice	
1123	wt	
mice	
Trichuris	
(6F)	
Presence	or	
absence	of	worms	
in	the	cecum	on	
day	33	as	
categorical	
measure.	
Hits	were	identified	by	
Fisher’s	exact	test	with	a	
p-value	cut-off	of	0.01,	
comparing	the	frequency	
of	positive	samples	in	
mutant	and	wt.	
all	wt	
animals	
287	genes	
289	strains	
1704	ko	
mice	
431	wt	mice	
DSS	and	
influenza	
survival	
data	
Number	of	mice	
having	to	be	culled	
because	of	
excessive	weight	
loss	before	the	end	
of	the	experiment		
Hits	were	identified	by	
Fisher’s	exact	test	with	a	
p-value	cut-off	of	0.01,	
comparing	the	frequency	
of	mice	with	above	
threshold	weight	loss	in	a	
mutant	strain	with	wt	
population,	combining	
data	from	both	sexes.	
all	wt	
animals	
as	for	DSS	
and	
influenza	
above	
	
*Please	note	that	Blood	hits	are	analysed	with	a	mixed	model	on	the	IMPC	website	as	the	
IMPC	statistical	pipeline	was	not	offering	the	option	of	a	reference	range	approach	at	the	
time	of	writing.	The	number	of	hits	for	blood	is	therefore	higher	on	the	IMPC	website.	
	 	
	 11	
Supplementary	Table	4:	Alleles	of	knockout	lines	included	in	the	study	
	
1700001C02Riktm1a(EUCOMM)Wtsi	 Dpy30tm1a(KOMP)Wtsi	 Pclaftm1a	(EUCOMM)Wtsi	
1700007K13Riktm2b(EUCOMM)Wtsi	 Duoxa2tm1b(KOMP)Wtsi	 Pdcd2tm1b(EUCOMM)Wtsi	
1700011A15Riktm1a(KOMP)Wtsi	 Dusp5tm1a(KOMP)Wtsi	 Pdia4tm1b	(EUCOMM)Wtsi	
1700024P04Riktm1b(EUCOMM)Wtsi	 Dynlrb2tm1a(KOMP)Wtsi	 Pdk3tm2a(KOMP)Wtsi	
1700029H14Riktm2b(KOMP)Wtsi	 Eci3tm1b(EUCOMM)Wtsi	 Pdzk1tm2b(EUCOMM)Wtsi	
1700034J05Riktm1a(KOMP)Wtsi	 Eif3htm1a(EUCOMM)Hmgu	 Pepdtm1a(KOMP)Wtsi	
1700067K01Riktm2a(KOMP)Wtsi	 Elac2tm1b(EUCOMM)Wtsi	 Pgap2tm1b(EUCOMM)Wtsi	
1700112E06Riktm1e(EUCOMM)Wtsi	 Ell2tm1b(EUCOMM)Wtsi	 Pigftm1a(KOMP)Wtsi	
1700123O20Riktm1a(EUCOMM)Wtsi	 Enc1tm1a(EUCOMM)Wtsi	 Pigltm1b(KOMP)Wtsi	
2010300C02Riktm1b(KOMP)Wtsi	 Enthd2tm1b(KOMP)Wtsi	 Pitrm1tm1a(KOMP)Wtsi	
2610034B18Riktm1b(EUCOMM)Wtsi	 Erlin2tm1a(EUCOMM)Wtsi	 Pitx1em1(IMPC)Wtsi	
3300002A11Riktm1a(KOMP)Wtsi	 Evi5tm1a(KOMP)Wtsi	 Pla2g6tm1a(EUCOMM)Wtsi	
3830406C13Riktm1b(KOMP)Wtsi	 Exoc3l2tm1b(KOMP)Wtsi	 Pld3tm1e(EUCOMM)Wtsi	
4930404H24Riktm1a(KOMP)Wtsi	 Exosc9tm1b(EUCOMM)Wtsi	 Plet1em1(IMPC)Wtsi	
4930590J08Riktm1a(EUCOMM)Wtsi	 Fads3tm1b(EUCOMM)Wtsi	 Plscr2tm1b(KOMP)Wtsi	
4931429L15Riktm1a(EUCOMM)Wtsi	 Fam122ctm1b(EUCOMM)Wtsi	 Plxnb3tm1a(KOMP)Wtsi	
4932431P20Rikem1(IMPC)Wtsi	 Fam160a1tm1b(EUCOMM)Wtsi	 Polbtm1a(KOMP)Wtsi	
4933402N03Riktm2a(KOMP)Wtsi	 Fam163atm2b(KOMP)Wtsi	 Pold3tm1b(EUCOMM)Wtsi	
4933434E20Riktm1a(EUCOMM)Wtsi	 Fam212btm1a(KOMP)Wtsi	 Polr3ftm1a(EUCOMM)Wtsi	
5730559C18Riktm2a(EUCOMM)Wtsi	 Fam47etm1a(EUCOMM)Wtsi	 Polr3gtm1a(EUCOMM)Wtsi	
9330182L06Riktm1a(KOMP)Wtsi	 Fam69atm1a(EUCOMM)Wtsi	 Ppil3tm1b(EUCOMM)Wtsi	
A430005L14Riktm1a(KOMP)Wtsi	 Fam71btm1a(KOMP)Wtsi	 Prametm1a(KOMP)Wtsi	
A430078G23Riktm1a(KOMP)Wtsi	 Fam92atm1b(KOMP)Wtsi	 Prkab1tm1b(KOMP)Wtsi	
A730017C20Riktm1b(KOMP)Wtsi	 Fbf1tm1a(EUCOMM)Wtsi	 Prrc2btm1a(EUCOMM)Wtsi	
Abhd14atm2a(EUCOMM)Wtsi	 Fbxo33tm1b(EUCOMM)Wtsi	 Prrg2tm1b(EUCOMM)Wtsi	
Abhd17atm1a(KOMP)Wtsi	 Fbxw26tm1b(KOMP)Wtsi	 Prrt2tm1a(KOMP)Wtsi	
Acbd5tm1b(EUCOMM)Wtsi	 Fdft1tm1a(KOMP)Wtsi	 Prss52tm2a(KOMP)Wtsi	
Acer1tm1a(EUCOMM)Wtsi	 Fkbp3tm2a(EUCOMM)Wtsi	 Psphtm1a(EUCOMM)Hmgu	
Actl10tm1a(EUCOMM)Wtsi	 Fnip2tm1a(KOMP)Wtsi	 Pth1rtm1a(EUCOMM)Hmgu	
Adaltm1a(EUCOMM)Wtsi	 Fryltm1b(KOMP)Wtsi	 Pthtm1a(EUCOMM)Wtsi	
Adamts19tm4a(EUCOMM)Wtsi	 Fxyd3tm1a(KOMP)Wtsi	 Ptprdtm2a(KOMP)Wtsi	
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Adamts3tm1b(KOMP)Wtsi	 Fzd6tm2a(EUCOMM)Wtsi	 Pwp1tm1a(EUCOMM)Wtsi	
Adap1tm1a(EUCOMM)Wtsi	 Galnt18tm1b(KOMP)Wtsi	 Pycr2tm1a(EUCOMM)Wtsi	
Adcy2tm1a(KOMP)Wtsi	 Galntl5tm1b(KOMP)Wtsi	 Rab17tm1a(KOMP)Wtsi	
Adcy9tm1b(EUCOMM)Wtsi	 Gbp5em1(IMPC)Wtsi	 Rab21tm1b(KOMP)Wtsi	
Adgrd1tm1b(EUCOMM)Wtsi	 Gdatm1a(KOMP)Wtsi	 Raph1tm1b(EUCOMM)Wtsi	
Adpgktm2a(EUCOMM)Wtsi	 Gdpd2tm1a(KOMP)Wtsi	 Rbaktm1b(KOMP)Wtsi	
Agap1tm1a(EUCOMM)Wtsi	 Gimap6tm1a(KOMP)Wtsi	 Rbm14tm1a(KOMP)Wtsi	
Aicdatm1b(EUCOMM)Hmgu	 Glo1tm1a(KOMP)Wtsi	 Rbm33tm1b(EUCOMM)Wtsi	
Aldh1b1tm2a(EUCOMM)Wtsi	 Glyatl3em1(IMPC)Wtsi	 Rbm47tm1a(EUCOMM)Wtsi	
Aldh3b1tm1b(EUCOMM)Wtsi	 Gm12253tm1a(KOMP)Wtsi	 Rbmxtm2b(KOMP)Wtsi	
Alox12etm1b(EUCOMM)Wtsi	 Gm13119tm2b(KOMP)Wtsi	 Reg3dtm1b(EUCOMM)Wtsi	
Alpk1em1(IMPC)Wtsi	 Gm13125tm1b(KOMP)Wtsi	 Repin1tm1a(EUCOMM)Wtsi	
Amz2tm1e(KOMP)Wtsi	 Gm16432tm1b(KOMP)Wtsi	 Ridatm1a(KOMP)Wtsi	
Ankrd13dtm1a(KOMP)Wtsi	 Gm16515tm1b(EUCOMM)Wtsi	 Rimbp2em1(IMPC)Wtsi	
Ankrd6tm1b(KOMP)Wtsi	 Gm5544tm1a(KOMP)Wtsi	 Rnasektm1b(EUCOMM)Wtsi	
Ankrd9tm1(KOMP)Wtsi	 Gmdstm1a(KOMP)Wtsi	 Rnf10tm1b(KOMP)Wtsi	
Anks6tm1b(KOMP)Wtsi	 Gmnctm1b(KOMP)Wtsi	 Rnf125tm1a	(EUCOMM)Wtsi	
Ano10tm1a(EUCOMM)Wtsi	 Gnb3tm1b(EUCOMM)Wtsi	 Rnf138tm1b(EUCOMM)Hmgu	
Anxa9tm1b(EUCOMM)Wtsi	 Gpbp1l1tm1a(EUCOMM)Wtsi	 Rnf157tm1b(EUCOMM)Wtsi	
Ap2a2em1(IMPC)Wtsi	 Gpr152tm1b(EUCOMM)Wtsi	 Rpiatm1a(KOMP)Wtsi	
Ap4e1tm1b(KOMP)Wtsi	 Gpr35tm1b(EUCOMM)Hmgu	 Rspo4tm1a(KOMP)Wtsi	
Ap4m1tm1b(EUCOMM)Wtsi	 Grb7tm1b(EUCOMM)Wtsi	 Rundc1tm1b(EUCOMM)Wtsi	
Apiptm1b(EUCOMM)Wtsi	 Grsf1tm1b(EUCOMM)Wtsi	 Rwdd1tm1b(KOMP)Wtsi	
Apol9btm2a(KOMP)Wtsi	 Gsdmetm1b(KOMP)Wtsi	 Sap130tm1a(KOMP)Mbp	
Apootm1b(KOMP)Wtsi	 Gsto2tm2a(KOMP)Wtsi	 Scaf11em1(IMPC)Wtsi	
Arap2tm2b(EUCOMM)Wtsi	 Gt(ROSA)26SorROSA26_Dre_C03	 Selenowtm1b(EUCOMM)Wtsi	
Arhgap17tm1b(EUCOMM)Wtsi	 Gtf2a1tm1a(KOMP)Wtsi	 Sept10tm1a(KOMP)Wtsi	
Arhgap22tm1a(KOMP)Wtsi	 Gtf2h2tm1a(EUCOMM)Wtsi	 Serinc3tm1a(KOMP)Wtsi	
Arhgef1tm1a(EUCOMM)Wtsi	 H13tm1b(KOMP)Wtsi	 Setd5tm1a(EUCOMM)Wtsi	
Arid1btm1b(EUCOMM)Hmgu	 Hao2em1(IMPC)Wtsi	 Sfxn3tm1b(KOMP)Wtsi	
Armc7tm1.1(KOMP)Wtsi	 Hbs1ltm1a(KOMP)Wtsi	 Sgms1tm1a(EUCOMM)Wtsi	
Armh3tm1a(EUCOMM)Wtsi	 Hecw2tm1a(EUCOMM)Wtsi	 Sgsm1tm1b(EUCOMM)Wtsi	
Arpc1btm1a(EUCOMM)Wtsi	 Herc1em1-3(IMPC)Wtsi**	 Sh3bgrl3tm2b(EUCOMM)Wtsi	
	 13	
Arrdc5tm1b(EUCOMM)Wtsi	 Hibadhtm1b(EUCOMM)Wtsi	 Sh3bp4tm1a(EUCOMM)Wtsi	
Art4tm1a(KOMP)Wtsi	 Hmgxb3tm1a(EUCOMM)Wtsi	 Sh3pxd2atm1b(EUCOMM)Wtsi	
Atad3atm1a(KOMP)Wtsi	 Homeztm1e(KOMP)Wtsi	 Sik3tm1a(EUCOMM)Hmgu	
Atg16l2tm1a(EUCOMM)Wtsi	 Hpf1em1(IMPC)Wtsi	 Slamf9tm1b(EUCOMM)Wtsi	
Atp11atm1a(KOMP)Wtsi	 Hrnrem1(IMPC)Wtsi	 Slc16a4tm2e(EUCOMM)Wtsi	
Atp5etm1b(EUCOMM)Wtsi	 Ifi27tm1b(EUCOMM)Wtsi	 Slc25a20tm1a(EUCOMM)Wtsi	
Atp5f1tm1b(EUCOMM)Wtsi	 Ifitm6tm1b(EUCOMM)Wtsi	 Slc25a28tm1b(EUCOMM)Wtsi	
Atp8b2tm1a(KOMP)Wtsi	 Ifnar1tm2a(EUCOMM)Wtsi	 Slc38a2tm1a(KOMP)Wtsi	
Atxn10tm1b(KOMP)Wtsi	 Ifnlr1tm1a(EUCOMM)Wtsi	 Slc5a7tm1a(KOMP)Wtsi	
Atxn3tm1a(KOMP)Wtsi	 Ift140tm1a(KOMP)Wtsi	 Slc9a3r2tm2a(EUCOMM)Hmgu	
Bach2tm1a(EUCOMM)Wtsi	 Il1r2tm1a(EUCOMM)Wtsi	 Slitrk4tm1b(KOMP)Wtsi	
Bai1tm2a(EUCOMM)Wtsi	 Il23rtm2a(EUCOMM)Wtsi	 Slu7tm1a(KOMP)Wtsi	
Bap1tm1a(EUCOMM)Hmgu	 Il27tm1b(EUCOMM)Wtsi	 Slx4iptm1a(EUCOMM)Wtsi	
Barhl1tm1(EGFP_CreERT2)Wtsi	 Irak1tm1b(EUCOMM)Hmgu	 Smg9tm1b(EUCOMM)Wtsi	
Bivmtm1b(KOMP)Wtsi	 Irf5tm1e(EUCOMM)Wtsi	 Smpd4tm2b(KOMP)Wtsi	
Bnip2tm1b(EUCOMM)Wtsi	 Izumo1rtm2a(KOMP)Wtsi	 Snx31tm1a(KOMP)Wtsi	
Bpgmtm1a(KOMP)Wtsi	 Josd1em1(IMPC)Wtsi	 Snx8tm2a(EUCOMM)Hmgu	
Bpifb1tm1e(KOMP)Wtsi	 Kat2bem1(IMPC)Wtsi	 Spata25tm1(KOMP)Wtsi	
Bpifb5tm2a(KOMP)Wtsi	 Kcnh4tm1b(KOMP)Wtsi	 Spink14tm1e(KOMP)Wtsi	
Brd2em1(IMPC)Wtsi	 Keraem1(IMPC)Wtsi	 Sqletm1a(EUCOMM)Wtsi	
Camkmttm1b(EUCOMM)Wtsi	 Kif13btm1b(EUCOMM)Wtsi	 Srsf7tm1a(EUCOMM)Wtsi	
Camsap3tm1a(EUCOMM)Wtsi	 Kif18btm1a(EUCOMM)Wtsi	 Ssr2tm1b(EUCOMM)Wtsi	
Capn11tm1b(EUCOMM)Wtsi	 Kif1bptm1a(KOMP)Wtsi	 Stard8tm1b(EUCOMM)Wtsi	
Capza2tm1b(KOMP)Wtsi	 Kif24tm1b(KOMP)Wtsi	 Stau2tm1a(EUCOMM)Wtsi	
Card9tm1a(EUCOMM)Hmgu	 Kif3btm1b(EUCOMM)Wtsi	 Stxbp4tm1a(EUCOMM)Wtsi	
Casc4tm2b(EUCOMM)Wtsi	 Klc2tm1e(EUCOMM)Wtsi	 Sult1c1tm1b(KOMP)Wtsi	
Catiptm1b(KOMP)Wtsi	 Klf17tm1b(KOMP)Wtsi	 Supt3tm1a(EUCOMM)Hmgu	
Cbr2tm1b(EUCOMM)Hmgu	 Klhl18tm1a(KOMP)Wtsi	 Supt5tm2a(KOMP)Wtsi	
Ccdc127tm1b(EUCOMM)Wtsi	 Klhl30tm1a(KOMP)Wtsi	 Tbc1d22atm1b(KOMP)Wtsi	
Ccdc159tm1a(KOMP)Wtsi	 Klk5tm2a(KOMP)Wtsi	 Tceal5tm1b(KOMP)Wtsi	
Ccdc18tm1a(EUCOMM)Wtsi	 Klk6em1(IMPC)Wtsi	 Tcf7l2tm1a(EUCOMM)Wtsi	
Ccdc69tm1b(KOMP)Wtsi	 Klrb1atm1a(KOMP)Wtsi	 Tchptm1a(EUCOMM)Wtsi	
Ccdc6em1(IMPC)Wtsi	 Krt31tm1e(KOMP)Wtsi	 Tcp11tm1a(EUCOMM)Wtsi	
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Cdkn2aipnltm1b(KOMP)Wtsi	 Krt7tm1b(KOMP)Wtsi	 Tctex1d2tm1e(EUCOMM)Wtsi	
Celf4tm1a(EUCOMM)Wtsi	 Krt83tm1b(KOMP)Wtsi	 Tead3tm1a(EUCOMM)Wtsi	
Cenpltm1b(EUCOMM)Wtsi	 L3mbtl2tm2a(EUCOMM)Wtsi	 Tent5ctm1b(KOMP)Wtsi	
Cep250tm1a(EUCOMM)Wtsi	 Larstm1b(KOMP)Wtsi	 Tet1tm1a(KOMP)Wtsi	
Cfap53em1(IMPC)Wtsi	 Lce1mtm1b(EUCOMM)Wtsi	 Tex38tm1a(KOMP)Wtsi	
Cfap61tm2a(EUCOMM)Wtsi	 Lce3ctm2a(EUCOMM)Wtsi	 Tgfb1i1tm1b(KOMP)Wtsi	
Cgrrf1tm1b(KOMP)Wtsi****	 Ldhbtm1b(KOMP)Wtsi	 Tgm6tm1a(KOMP)Wtsi	
Chd9tm1a(EUCOMM)Wtsi	 Ldlrad4tm1b(EUCOMM)Wtsi	 Timelesstm1b(EUCOMM)Hmgu	
Chil4tm1b(EUCOMM)Hmgu	 Leo1tm1a(EUCOMM)Wtsi	 Timmdc1tm1b(EUCOMM)Wtsi	
Chmp6tm1b(KOMP)Wtsi	 Leprottm2b(KOMP)Wtsi	 Tmc3tm2b(KOMP)Wtsi	
Chst11tm1a(KOMP)Wtsi	 LmnaG609G***	 Tmem110tm2b(KOMP)Wtsi	
Chtoptm1a(EUCOMM)Wtsi	 Lonrf3tm1b(KOMP)Wtsi	 Tmem126atm1a(EUCOMM)Wtsi	
Cir1tm3a(KOMP)Wtsi	 Lpxntm1b(EUCOMM)Hmgu	 Tmem127tm1(KOMP)Wtsi	
Clpptm1a(EUCOMM)Wtsi	 Lrmptm1b(EUCOMM)Wtsi	 Tmem18tm1b(EUCOMM)Wtsi	
(Cluster5N1)(tm1)Brd*	 Lrrc23tm1a(EUCOMM)Wtsi	 Tmem241tm1b(EUCOMM)Wtsi	
(ClusterXN1)tm1(Brd)*	 Lrrc71tm1a(KOMP)Wtsi	 Tmem254btm1a(KOMP)Wtsi	
Cmbltm1b(KOMP)Wtsi	 Lrrc8dtm1a(EUCOMM)Wtsi	 Tmem30atm1a(KOMP)Wtsi	
Cmtm5tm1a(KOMP)Wtsi	 Lyplal1tm1a(KOMP)Wtsi	 Tmem37tm1a(EUCOMM)Wtsi	
Cnbd1tm1b(EUCOMM)Wtsi	 Lyrm9tm1a(KOMP)Mbp	 Tmem42tm1b(KOMP)Wtsi	
Cnot4tm1b(EUCOMM)Wtsi	 Macrod1em1(IMPC)Wtsi	 Tomm20ltm1b(EUCOMM)Wtsi	
Cog6tm1a(EUCOMM)Wtsi	 Mamstrtm1b(EUCOMM)Wtsi	 Traf2tm1a(EUCOMM)Wtsi	
Col24a1tm1b(EUCOMM)Wtsi	 Mast2tm1a(KOMP)Wtsi	 Traf6tm2a(EUCOMM)Wtsi	
Col4a3bptm1a(KOMP)Wtsi	 Mau2tm1b(KOMP)Wtsi	 Trappc10tm1b(KOMP)Wtsi	
Coro6tm1e(EUCOMM)Wtsi	 Mbd1em1(IMPC)Wtsi	 Trappc9tm1a(EUCOMM)Wtsi	
Cpgi81tm1.1(NCC)WCS*	 Mbl2em1(IMPC)Wtsi	 Trem1tm1(KOMP)Vlcg	
Cpsf3tm1b(EUCOMM)Wtsi	 Mcf2ltm1a(EUCOMM)Hmgu	 Trim21em1(IMPC)Wtsi	
Cpt2tm1b(KOMP)Wtsi	 Med22tm1a(EUCOMM)Wtsi	 Trim25tm2b(EUCOMM)Hmgu	
Crim1em1(IMPC)Wtsi	 Med23em1(IMPC)Wtsi	 Trim56tm1a(EUCOMM)Wtsi	
Crlf3em1(IMPC)Wtsi	 Medagtm2b(KOMP)Wtsi	 Trim65tm1b(KOMP)Wtsi	
Crls1tm1a(EUCOMM)Wtsi	 Metrnltm1b(KOMP)Wtsi	 Trmt2atm2b(EUCOMM)Wtsi	
Csmd1em1(IMPC)Wtsi	 Mettl24tm1a(KOMP)Wtsi	 Trp53rkbtm1a(EUCOMM)Wtsi	
Csnk1g3tm1a(EUCOMM)Wtsi	 Mgat4ctm1a(EUCOMM)Wtsi	 Trub2tm2a(EUCOMM)Wtsi	
Ctr9tm1b(EUCOMM)Wtsi	 Mir32(tm1)Brd	 Tuba3atm1b(KOMP)Wtsi	
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Cttnbp2tm1b(KOMP)Wtsi	 Mir96tm2.2(IMPC)Wtsi	 Tuft1tm1a(KOMP)Wtsi	
Cutaltm1a(EUCOMM)Wtsi	 Mir122(tm1)Brd	 Ube2d1tm3e(EUCOMM)Wtsi	
Cxcr1tm1a	(EUCOMM)Wtsi	 Mir210(tm1)Brd	 Ubxn10tm1b(EUCOMM)Wtsi	
Cxcr2tm1a(EUCOMM)Wtsi	 Mir211(tm1)Brd	 Uevldtm1a(EUCOMM)Wtsi	
Cyp2b13tm1b(KOMP)Wtsi	 Mir342(tm1)Brd	 Umodl1tm1a(KOMP)Wtsi	
Cyp2r1tm1b(EUCOMM)Wtsi	 Mkrn2tm1b(KOMP)Wtsi/em1(IMPC)Wtsi**	 Uri1tm1a(EUCOMM)Wtsi	
D630023F18Riktm1b(KOMP)Wtsi	 Mospd1tm1a(KOMP)Wtsi	 Usp11tm1(KOMP)Wtsi	
D6Wsu163etm1b(EUCOMM)Wtsi	 Mpgtm1a(EUCOMM)Wtsi	 Usp20tm1a(EUCOMM)Hmgu	
D7Ertd443etm2a(KOMP)Wtsi	 Mrm1tm2a(EUCOMM)Wtsi	 Usp30tm2b(EUCOMM)Hmgu	
D930028M14Riktm1a(EUCOMM)Wtsi	 Mroh4tm1b(KOMP)Wtsi	 Usp37em1(IMPC)Wtsi	
Dact3tm1b(KOMP)Wtsi	 Mroh9tm1a(EUCOMM)Wtsi	 Usp5tm1a(EUCOMM)Hmgu	
Daf2tm1a(KOMP)Wtsi	 Mrps21tm1e(EUCOMM)Wtsi	 Vamp3tm2b(EUCOMM)Wtsi	
Daptm1a(KOMP)Mbp	 Mrps5tm1b(EUCOMM)Wtsi	 Vps13atm1b(EUCOMM)Wtsi	
Dapk2tm1b(EUCOMM)Wtsi	 Mybphltm1b(KOMP)Wtsi	 Vps33btm1a(EUCOMM)Wtsi	
Dbn1tm1b(KOMP)Wtsi	 Myh7btm1a(KOMP)Wtsi	 Vps51tm1a(KOMP)Wtsi	
Dcaf11tm1a(KOMP)Wtsi	 Myo10tm2(KOMP)Wtsi	 Vps72tm1a(EUCOMM)Wtsi	
Dcbld2tm1a(KOMP)Wtsi	 Myo9atm1b(EUCOMM)Wtsi	 Vwa3atm1b(KOMP)Wtsi	
Dcdc2btm1b(KOMP)Wtsi	 N6amt2tm1a(EUCOMM)Wtsi	 Wactm1b(EUCOMM)Wtsi	
Dclk1tm1a(EUCOMM)Wtsi	 Nacc2tm2b(EUCOMM)Wtsi	 Washc2tm2b(KOMP)Wtsi	
Dcnem1(IMPC)Wtsi	 Nadk2tm1b(EUCOMM)Wtsi	 Wdr89tm1a(KOMP)Wtsi	
Dctn4em1(IMPC)Wtsi	 Nat10tm1a(KOMP)Wtsi	 Wdtc1tm1a(KOMP)Wtsi	
Ddah1tm2a(EUCOMM)Wtsi	 Ncf2tm1a(EUCOMM)Wtsi	 Wnt16tm2b(EUCOMM)Wtsi	
Ddx42tm1b(EUCOMM)Wtsi	 Ndufb8tm1a(EUCOMM)Wtsi	 Wrap53tm1b(EUCOMM)Wtsi	
Ddx51tm1a(KOMP)Wtsi	 Nebltm1b(EUCOMM)Wtsi	 Xkrxtm1b(EUCOMM)Wtsi	
Defb14tm1b(KOMP)Wtsi	 Nek3tm1b(EUCOMM)Wtsi	 Xpnpep1tm1a(KOMP)Wtsi	
Defb22tm1a(KOMP)Wtsi	 Nek9tm1a(EUCOMM)Wtsi	 Xxylt1tm1a(EUCOMM)Hmgu	
Defb30tm2b(KOMP)Wtsi	 Nelfetm1a(EUCOMM)Wtsi	 Ydjctm1(KOMP)Wtsi	
Dennd1btm1a(EUCOMM)Hmgu	 Nfkbil1tm1a(KOMP)Wtsi	 Yipf7tm1e(KOMP)Wtsi	
Dennd1ctm1b(EUCOMM)Wtsi	 Nhlrc2tm1a(KOMP)Wtsi	 Ypel4tm1a(EUCOMM)Wtsi	
Dennd4ctm1b(EUCOMM)Wtsi	 Nipsnap3atm1b(KOMP)Wtsi	 Zbed5tm1b(EUCOMM)Wtsi	
Denrtm1b(KOMP)Wtsi	 Nme4tm1a(EUCOMM)Wtsi	 Zfp182tm1b(KOMP)Wtsi	
Dffbem1(IMPC)Wtsi	 Nmrk1tm1a(KOMP)Wtsi	 Zfp239tm1b(KOMP)Wtsi	
Dhodhtm1b(EUCOMM)Wtsi	 Npattm1b(EUCOMM)Wtsi	 Zfp266tm1b(EUCOMM)Wtsi	
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Dhpstm2a(EUCOMM)Wtsi	 Nrbp1tm3b(EUCOMM)Wtsi	 Zfp287tm1b(EUCOMM)Wtsi	
Dhx33tm1b(KOMP)Wtsi	 Nrde2tm2a(KOMP)Wtsi	 Zfp341tm1a(KOMP)Wtsi	
Dhx35tm1b(EUCOMM)Wtsi	 Nudt12tm1a(KOMP)Wtsi	 Zfp365tm1a(KOMP)Wtsi	
Dip2atm2b(KOMP)Wtsi	 Nup85tm1a(KOMP)Wtsi	 Zfp408tm1b(EUCOMM)Wtsi	
Dlg3tm1a(EUCOMM)Wtsi	 Nutm2tm2b(EUCOMM)Wtsi	 Zfp616tm1b(KOMP)Wtsi	
Dlg4tm1e(EUCOMM)Wtsi	 Nxntm1b(EUCOMM)Wtsi	 Zfp658tm1b(EUCOMM)Wtsi	
Dlk1em1(IMPC)Wtsi	 Oaftm1a(EUCOMM)Wtsi	 Zfp719tm1a(EUCOMM)Wtsi	
Dmgdhtm1a(KOMP)Wtsi	 Oog2tm1a(EUCOMM)Wtsi	 Zfp719tm1b(EUCOMM)Wtsi	
Dnah17tm1e(KOMP)Wtsi	 Orc1tm1a(KOMP)Wtsi	 Zfp763em1(IMPC)Wtsi	
Dnajc8tm1b(KOMP)Wtsi	 Os9tm1a(EUCOMM)Wtsi	 Zfp791tm1a(KOMP)Wtsi	
Dnase1l2tm1.1(KOMP)Wtsi	 Osbpl3tm1a(EUCOMM)Wtsi	 Zfp84tm1b(KOMP)Wtsi	
Dnmt3atm1a(KOMP)Wtsi	 Otud7btm1b(EUCOMM)Wtsi	 Zfp879tm2b(KOMP)Wtsi	
Dnpeptm1e(EUCOMM)Wtsi	 Pam16tm1b(EUCOMM)Wtsi	 Zfyve28tm1b(EUCOMM)Wtsi	
Dph6tm1a(KOMP)Wtsi	 Pced1atm1b(EUCOMM)Wtsi	 Zranb1tm1a(EUCOMM)Hmgu	
Dpm1tm1b(KOMP)Wtsi	 	 	
	
*	Knockouts	of	multi-gene	or	regulatory	regions:		
Cluster	5N1:	mmu-mir-25	(ENSMUSG00000065394),	mmu-mir-93	(ENSMUSG00000065527),	
mmu-mir-106b	(ENSMUSG00000065514)	
ClusterXN1:	ENSMUSG00000070106,	ENSMUSG00000065613	ENSMUSG00000065473,	
ENSMUSG00000076041	ENSMUSG00000077111,	ENSMUSG00000065456	
Cpgi81:	CpG	island	81,	Chr1:23255875-23257106	bp	
**	More	than	one	mouse	line	has	been	phenotyped	for	these	genes.	
***	The	Lmna	allele	is	not	an	IMPC	allele	and	has	been	described	previously62.	
****	The	Cgrrf1	ko	strain	has	a	mixed	C57BL/6N;	C57BL/6NTac	background.	
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Supplementary	Table	5:	Key	resources	
	
REAGENT	or	RESOURCE	 SOURCE	 IDENTIFIER	
Antibodies	
CD3ε	Functional	grade	purified,	clone	
eBio500A2	
eBioscience	
16-0033-86;	
RRID:	AB_842782	
CD3ε	BV421,	clone	145-2C11	 BD	Biosciences	 562600	
CD3ε	BV785,	clone	145-2C11	 BioLegend	UK	Ltd	 100232	
CD4	PE,	clone	RM4-5	 BioLegend	UK	Ltd	
00511;	
RRID:	AB_312714	
CD4	BV510,	clone	RM4-5	 BioLegend	UK	Ltd	 100553	RRID:AB_2561388	
CD4	BV786,	clone	RM4-5	 BD	Biosciences	 563331	
CD5	APC,	clone	53-7.3	 BD	Biosciences	 550035	
CD5	BV510,	clone	53-7.3	 BD	Biosciences	 563069	
CD8a	APC,	clone	53-6.7	 BioLegend	UK	Ltd	
100712;	
RRID:	AB_312750	
CD8α	AF700,	clone	53-6.7	 BD	Biosciences	 557959	
CD8α	APC-H7,	clone	53-6.7	 BD	Biosciences	 560182	RRID:AB_1645237	
CD11b	BV510,	clone	M1/70	 BioLegend	UK	Ltd	 101245	
CD11b	PE-Cy7,	clone	M1/70	 BioLegend	UK	Ltd	 101216	RRID:AB_312799	
CD11c	BV786,	clone	HL3	 BD	Biosciences	 563735	
CD19	BV421,	clone	ID3	 BD	Biosciences	 562701	
CD19	PE-CF594,	clone	ID3	 BD	Biosciences	 562291	RRID:AB_11154223	
CD19	PECY7,	clone	ID3	 BD	Biosciences	 552854	
CD21/35	FITC,	clone	7G6	 BD	Biosciences	 553818	
CD21/35	PE,	clone	7G6	 BD	Biosciences	 552957	
CD23	BV421,	clone	B3B4	 BD	Biosciences	 562929	
CD24	APC,	clone	M1/69	 BD	Biosciences	 562349	
CD25	APC,	clone	PC61	 BD	Biosciences	 557192	
CD25	PE,	clone	PC61		 BioLegend	UK	Ltd	 102008	RRID:AB_312857	
CD28	Functional	grade	purified,	clone	
37.51	
eBioscience	
16-0281-86;RRID:	
AB_468923	
CD43	PerCP-Cy5.5	 BioLegend	UK	Ltd	 121224	
CD44	FITC,	clone	1B11	 BD	Biosciences	 553133	
CD44	FITC,	clone	IM7		 BD	Biosciences	 561859	RRID:AB_10894581	
CD45	Alexa	700,	clone	30-F11	 BioLegend	UK	Ltd	 103128	RRID:AB_493715	
CD45	e450,	clone	30-F11	 eBioscience	 48-0451-82	
CD45	eVolve™	605	(Qdot),	clone	30-F11	 eBioscience	 83-0451-42	
CD45	eFluor450,	clone	30-F11	 eBioscience	 48-0451-82	
CD45R	(B220)	PeCY7,	clone	RA3-6B2	 BioLegend	UK	Ltd	 103222	
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CD45R	(B220)	AF700,	clone	RA3-6B2	 BD	Biosciences	 557957	
CD62L	PE-CF594,	clone	MEL-14	 BD	Biosciences	 562404	RRID:AB_11154046	
CD62L	PerCP	Cy5.5,	clone	MEL-14	 BD	Biosciences	 560513	
CD86	PECY7,	clone	GL1	 BD	Biosciences	 560582	
CD95	PECY7,	clone	Jo2	 BD	Biosciences	 557653	
CD103	PE,	M290	 BD	Biosciences	 557495	
CD115	APC,	clone	AF598	 BioLegend	UK	Ltd	 135510	RRID:AB_2085221	
CD138	BV650,	clone	281-2	 BioLegend	UK	Ltd	 142517	
CD161	(NK1.1)	BV421,	clone	PK136	 BioLegend	UK	Ltd	 108732	RRID:AB_2562218	
CD161	(NK1.1)	BV650,	clone	PK136	 BioLegend	UK	Ltd	 108736	
CD317	BV650,	clone	927	 BioLegend	UK	Ltd	 127019	
F4/80	PerCP-Cy5.5,	clone	BM8	 BioLegend	UK	Ltd	 123128	
Fc	block	 BD	Biosciences	 553142	
GITR	PE,	clone	DTA-1	 BD	Biosciences	 558119	
GL-7	AF647,	clone	GL7	 BD	Biosciences	 561529	
Gr-1	AF700,	clone	RB6-8C5	 BioLegend	UK	Ltd	 108422	
Ig	HRP,	polyclonal	 Dako	 P0447	
IgG	(H+L)	FITC,	polyclonal	 Invitrogen	 626511	
IgG1	HRP,	clone	X56	 BD	Biosciences	 559626	
IgG2a	HRP,	clone	R19-15	 BD	Biosciences	 553391	
IgD	BV510,	clone	11-26c.2a	 BD	Biosciences	 563110	
IgD	PerCP-Cy5.5,	clone	11-26c.2a	 BioLegend	UK	Ltd	 405710	
IgD	AF488,	clone	11-26c.2a	 BioLegend	UK	Ltd	 405718	
IgG1	PE,	clone	A85-1	 BD	Biosciences	 550083	
IgM	BV42,	clone	RMM-1	 BioLegend	UK	Ltd	 406518	
IgM	BV786,	clone	R6-60.2	 BD	Biosciences	 564028	
KLRG1	BV421,	clone	2F1	 BD	Biosciences	 562897	
KLRG1	PE-Cy7,	clone	2F1	 BioLegend	UK	Ltd	 138416	RRID:AB_2561736	
Ly-51	PE,	clone	BP-1	 BD	Biosciences	 553735	
Ly6B	FITC,	clone	7/4	 AbD	Serotec	 MCA771FB	RRID:AB_324596	
Ly6C	AF700,	clone	AL-21	 BD	Biosciences	 561237	
Ly6C	PerCP-Cy5.5,	clone	HK1.4	 BioLegend	UK	Ltd	 128012	RRID:AB_1659241	
Ly6G	APC,	clone	1A8	 BD	Biosciences	 560599	
Ly6G	V450,	clone	1A8	 BD	Biosciences	 560603	RRID:AB_1727564	
MHC	II	I-A/I-E	PE,	clone	M5/114.15.2	 BioLegend	UK	Ltd	 107608	RRID:AB_313323	
MHC	II	I-A/I-E	AF647,	
clone	M5/114.15.2	
BioLegend	UK	Ltd	
107618	
MHC	II	I-A/I-E	FITC,	2G9	 BD	Biosciences	 553623	
MHC	II	I-A/I-E	AF647,	
clone	M5/114.15.2	
BioLegend	UK	Ltd	
107618	
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Vγ5	(aka	Vγ3)	FITC,	clone	536	 BD	Biosciences	 553229	
TCRβ	PerCP-Cy5.5,	clone	H57-597	 BioLegend	UK	Ltd	 109228	RRID:AB_1575173	
TCRδ	PE	CY7,	clone	GL3	 BioLegend	UK	Ltd	 118124	
TCRδ	APC,	clone	GL3	 BioLegend	UK	Ltd	 118116	RRID:AB_1731813	
   
Chemicals,	Peptides,	and	Recombinant	Proteins	
10mM	HEPES	 Life	Signalling	
Technologies	
15630056	
Collagenase	 Sigma	Aldrich	-	
Roche		
11088858001	
DNAase	 Sigma		 DN25	
RBC	lysis	buffer	 eBioscience	 00-4300-54	
EDTA	(0.5	M),	pH	8.0	 Life	Technologies	 AM9261	
Prolong	Gold	Mounting	Medium	 New	England	
Biolabs	
9071S	
Zombie	NIR	Fixable	Viability	Kit	 Biolegend	 423106	
BD	FACSDiva	CS&T	Research	Beads	 BD	Biosciences	 655051	
Ammonium	thiocyanate	 Sigma	 A7149-100G	
NairTM	moisturizing	hair	removal	cream	 Church	&	Dwight	
Co.	
N/A	
Acetone	 VWR	 20067-320	
Fetal	Bovine	Serum	 Gibco	 FBS	
Fetal	Bovine	Serum	 Hyclone	laboratories	
-	Biosera	
FB-1001/500	
RPMI	1640	 GIBCO	-	life	
technologies	
21875034	
RPMI	1640	(no	phenol	red)	 GIBCO	-	life	
technologies	
32404014	
PBS	10x	(neg	for	CA2+	and	Mg2+)		 Gibco	 14200-067	
PBS	10x	(with	calcium	&	Magnesium)	 Gibco	 14080-048	
PBS,	D’Beccos	 GIBCO	-	life	
technologies	
14190094	
D-MEM	(HG)	 GIBCO	-	life	
technologies	
41966029	
DPBS	 	 Sigma-Aldrich	 D8662	
Water	 Sigma-Aldrich	 W3500	
Mounting	Medium	Dropper	Vial	5mL	 A.	Menarini	
Diagnostics	Ltd.	
38015	
2-mercaptoethanol	 GIBCO	Invitrogen	 31350010	
L-Glutamine	 GIBCO	Invitrogen	 25030024	
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Recombinant	murine	IL-2	 Peprotech	 212-12-100	
Penicillin/Streptomycin	 Sigma-Aldrich	 P4333	
Sodium	Pyruvate	MEM	 Sigma-Aldrich	 11360039	
Dextran	sulfate,	sodium	salt	 Affymetrix,	Inc.	 14489;	CAS#	9011-18-1	
Formaldehyde	4%	solution	 VWR	international	
ltd	
9713.5000	
BSA	 Sigma-Aldrich	 A9056	
Sigmafast	 Sigma-Aldrich	 P9187	
LB	 Oxoid	 CM1018	
Ampicillin	 Roche	 10	835	242	001	
Tween	20	 Sigma-Aldrich	 P1379	
	 	 	
Critical	Commercial	Assays	
Zenit	ANA	HEp-2	Cells	(12	wells)	 A.	Menarini	
Diagnostics	Ltd.	
37806	
FITC	–	QC	Slide	 A.	Menarini	
Diagnostics	Ltd.	
38015	
Cytotox	96	non-radioactive	assay	 Promega	UK	Ltd		 	G1780	
	 	 	
Deposited	Data	
3i	statistical	analysis	 This	study	 www.immunophenotype.org	
Raw	and	analyzed	data	 This	study	 www.immunophenotype.org	
	 	 	
Experimental	Models:	Cell	Lines	
P815	mastocytoma	cell	line	 ATTC	 TIB-64	
HEp-2	cell	lines,	coated	on	slides	 A.	Menarini	
Diagnostics	Ltd.	
37806	
	 	 	
Experimental	Models:	Organisms/Strains	
C57BL/6N	wild	type	control	mice	 WTSI	 	
Knockout	mouse	strains	as	detailed	in	
Table	S4	
WTSI	 	
Salmonella	typhimurium	M525	::	TetC	 Gordon	Dougan,	
WTSI	
	
Trichuris	muris	 Richard	Grencis,	
University	of	
Manchester	
	
	 	 	
Equipment	
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Scil	Vetabc	hematology	analyser	 Horiba	 http://www.horiba.com/uk/
medical/products/animal-
healthcare/haematology/scil
-vet-abc-details/scil-vet-abc-
12687/	
BD	LSR	II	flow	cytometer	(Blood)	 BD	Biosciences	 RRID:SCR_002159;	
http://www.rockefeller.edu/
fcrc/pdf/BD_LSRII_Brochure_
SJ-0142-00.pdf	
BD	LSR	Fortessa	X-20	(Spleen,	MLN,	and	
bone	marrow)	
BD	Biosciences	 http://www.bdbiosciences.c
om/us/instruments/research
/cell-analyzers/bd-
lsrfortessa-x-
20/m/1519232/overview	
Leica	SP2	confocal	microscopes,	40x	
1.25	NA	oil	immersion	lens	and	405	nm,	
488	nm	and	633	nm	lasers	(Ear	
epidermis)	
Leica	 https://www.leica-
microsystems.com/products
/confocal-
microscopes/details/product
/leica-tcs-sp2/	
Leica	SP5	confocal	microscopes,	40x	
1.25	NA	oil	immersion	lens	and	405	nm,	
488	nm	and	633	nm	lasers	(ear	
epidermis)	
Leica	 https://www.leica-
microsystems.com/products
/confocal-
microscopes/details/product
/leica-tcs-sp5/	
Nikon	wide-field	TE2000U	Microscope	
(ANA)	
Nikon	 TE2000U	
Deltavision	Elite	widefield	system	based	on	an	Olympus	microscope,	LED	light	source	and	CoolSNAP	HQ2	camera	(ANA)	
	
GE	Healthcare	Life	
Sciences,	Olympus	
	
https://www.gelifesciences.c
om/en/us/shop/deltavision-
elite-high-resolution-
microscope-p-04420	
Zeiss	AxioPlan	Microscope	with	a	Plan	
Neofluar	5x/0.15	Ph1	objective	and	
Moti	Cam	10	camera	(DSS)	
Zeiss	 https://www.zeiss.com/micr
oscopy/int/home.html?gclid
=EAIaIQobChMIj7KRv-
mH4QIVybHtCh0C3w_OEAA
YASAAEgJ2afD_BwE	
	 	 	
Software	and	Algorithms	
R	version	3.3.1	-3.5.2	and	general	data	
analysis	packages	(data.table,	ggplot2,	
dplyr,	igraph,	MASS)	
The	R	project	for	
statistical	
computing	
www.r-project.org	
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PhenStat_2.8	
org.Hs.eg.db	
org.Mm.eg.db	
BioConductor	 www.bioconductor.org	
RStudio	1.0.136	 RStudio	 https://www.rstudio.com	
R	code	for	reference	range	analysis,	
assessment	of	false	positive	rate	
Anna	Lorenc	 https://github.com/AnnaLor
enc/3i_heatmapping	
available	on	request	
Flow	Jo	v1.10	 Treestar	 RRID:SCR_008520;	
http://www.flowjo.com	
Cytoscape	3.6.1	 Cytoscape	 www.cytoscape.org	
BD	DIVA	7.0	 BD	Biosciences	 RRID:SCR_001456;	
http://www.bdbiosciences.c
om/instruments/software/fa
csdiva/index.jsp	
flowClean	 Ryan	Brinkman	 Fletez-Brant	et	al	2016	
UFO	 Ryan	Brinkman	 available	on	request	
flowDensity	 Ryan	Brinkman	 Malek	et	al	2015	
PRISM	6	 Graphpad	software	 http://www.graphpad.com/s
cientific-software/prism/	
Definiens	developer	 Definiens	 www.definiens.com	
ANA	assay	Fiji/ImageJ	macro	 Katherine	Bull	 www.immunophenotype.org	
ANA	assay	Python	scoring	script	 Katherine	Bull	 www.immunophenotype.org	
Microsoft	Excel	2010	 Microsoft		 https://www.microsoftstore.
com/store/msuk/en_GB/ho
me		
	 	 	
Deposited	Data	
3i	statistical	analysis	 This	study	 www.immunophenotype.org	
Raw	and	analyzed	data	 This	study	 www.immunophenotype.org	
	 	 	
Other	
30	µm	CellTrics	filters	 Partec	Cell	Trics	 04-0042-2316	
96	Well	Clear	V-Bottom	Not	Treated	
Polypropylene	Microplate,	Nonsterile	
SLS	
	
353263	
	
Microtube	MaxyClear	PP	clear	1.7	mL	
(Axygen)	
Fisher	 12756799	
C-Tubes	 Miltenyi	Biotec	 130-096-334	
Superfrost	R	Plus	#72,	26x76x1	mm	(75	
pieces)	
VWR	 631-0108	
Cover	Glass	22	x	40	Mm	No.	1,5		 VWR	 631-1370	
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